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Abstract
Feline herpesvirus 1 (FHV-1) is a linear double-stranded DNA virus that causes
approximately 50% of the upper respiratory tract infections and produces the most severe
respiratory disease in domestic cats. Primary ocular infection, as occurs in humans with
the related virus, herpes simplex virus type 1 (HSV-1), consistently produces
conjunctivitis and minimal corneal involvement; however, clinical manifestations of
disease due to repeated recrudescence involve the cornea and can potentially lead to
blindness. Vaccines only produce partial protection from clinical disease, and antiviral
medications approved for treatment of HSV-1 in humans are only minimally effective for
treatment of the chronic cases in cats. Therefore, RNA interference (RNAi), a RNAguided gene regulatory mechanism that is found in a variety of eukaryotic organisms and
provides anti-viral immunity in plants, was used as a therapeutic method for prevention
of FHV-1 infection in feline cells. Previous RNAi experiments in related herpesviruses
demonstrated that the DNA polymerase gene and a gene coding for a viral attachment
protein are effective targets for inhibiting herpesvirus replication. Therefore, a region
coding for highly conserved amino acid motifs of herpesvirus DNA polymerase genes,
which is unique to each viral species and lacks DNA sequence drift for
alphaherpesviruses, including herpes simplex virus type 2 and also feline herpesvirus as
shown in this study, was targeted by RNAi. The attachment proteins for FHV-1 are
unknown, but the highly conserved glycoprotein D (gD) gene was also chosen as a target
for this study. HSV-1 gD is an essential receptor-binding polypeptide and is necessary
for penetration of the virus into cells. FHV-1 gD, an envelope protein, is an inducer of
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virus-neutralizing antibodies and may play an important role in the restriction of the host
range of the virus to feline cells.
Two synthetic siRNAs targeting the DNA polymerase gene and the gD gene of
FHV-1 were effective in knockdown of their intended targets by 69-83% for DNA
polymerase mRNA and 77-87% for gD mRNA, determined by quantitative real-time RTPCR. Based on flow cytometry results, glycoprotein D mRNA knockdown decreased gD
cell surface expression by 27-43%, and DNA polymerase mRNA interference decreased
cell surface FHV-1 glycoprotein expression by 29-71%. Knockdown of the mRNAs
from these genes also resulted in decreased infective virus in vitro, with decreased viral
replication by 83-96% by DNA polymerase RNAi and 77-84% by gD RNAi, determined
by plaque assays. Interference of each mRNA also resulted in a decrease in the amount
of the opposite mRNA, independent of interferon β production. These results indicate
that FHV-1 glycoprotein D, like its homolog in HSV-1, is essential for in vitro replication
and is likely involved with viral attachment and/or penetration, and both this gene and the
FHV-1 DNA polymerase gene are suitable targets for RNAi anti-viral treatment. This
study lays the groundwork for potential in vivo investigations in cats. Such studies may
provide unique insights into the prevention/treatment of herpesvirus infections by RNAi.
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Part 1 General Introduction
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Introduction
Feline herpesvirus 1 (FHV-1) is a linear double-stranded DNA virus (185) that
causes approximately 50% of the upper respiratory tract infections (140) and produces
the most severe respiratory disease in domestic cats (173). This virus is labile in nature
but maintains itself by producing latent infections in its host (55). Killed and modified
live vaccines are available for FHV-1, but because the virus is poorly immunogenic (8),
the vaccines do not prevent infection and only produce partial protection from clinical
disease (21). Acute infections are usually localized to the respiratory tract and clinical
signs, though potentially severe, usually resolve in a few weeks (173). However, chronic
disease in latently infected cats is problematic. First, diagnosing the disease is difficult in
these cats (140). Approximately 70% of cats are seropositive for the virus (106), and
about 80% of infected cats become latently infected (55). Though the majority of latently
infected cats do not develop chronic clinical disease (6), there is still a large percentage of
adult cats that have this problem (210). Therefore, a positive test result may mean FHV1 is the cause of the disease, found coincidentally as a result of intermittent shedding, or
present secondary to stress caused by a separate disease that is primarily responsible for
the clinical signs (27, 137).
Second, the clinical manifestations of disease due to repeated recrudescence,
mainly affecting the eye, are significant and can potentially lead to blindness (6).
Antiviral medications approved for treatment of a related virus, herpes simplex virus type
1 in humans, are only minimally effective for treatment of these chronic cases in cats
(212). Therefore, development of a new therapeutic for FHV-1 would be beneficial.
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Recently, RNA interference has been used for prevention of various mammalian
viral infections both in vitro and in vivo (98). RNA interference is a RNA-guided gene
regulatory mechanism that is found in a variety of eukaryotic organisms, including yeast,
plants, and mammals. One of its biological functions is anti-viral immunity in plants
(39). This defense mechanism is triggered by double stranded RNA, and small
interfering RNAs can be chemically produced and delivered to cells to silence specific
genes of interest (47). The purpose of this study was to determine the feasibility of using
RNA interference to prevent feline herpesvirus 1 infections in vitro.
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Feline Herpesvirus 1 Literature Review
Feline herpesvirus 1 was first isolated in the United States in 1957 from a group
of 5-10 week old kittens experiencing upper respiratory tract disease (38). The virus was
subsequently detected in many other countries, including Switzerland in 1963 (35),
Hungary in 1965 (82), Canada in 1965 (46), Britain in 1966 (88), Australia in 1970 (216),
and Japan in 1974 (125).
Classification and viral properties: FHV-1 is a member of the family
Herpesviridae (46) and is classified in the subfamily Alphaherpesvirinae (184). Based
on phylogenetic analysis of its proteins, FHV-1 is grouped in the Varicellovirus genus
(126, 246).
FHV-1 has a diameter between 141 and 173 mµ, contains an icosahedral capsid
comprising 162 capsomers, and has an envelope (34, 35). The genome of FHV-1 is
approximately 126-134 kbp, based on restriction endonuclease mapping (67, 185). It has
a G+C content of approximately 46% (172). The genome consists of a single linear
molecule of double-stranded DNA. It is composed of a unique long region
approximately 99-104kbp, which is covalently linked to a unique short sequence of 8-9
kbp that is flanked by inverted repeats of 7-11 kpb each (67, 185). The short region can
invert its orientation relative to the long region, so the genome exists in two isomeric
forms. FHV-1 has a group D genome, which includes other alphaherpesviruses varicellazoster virus, pseudorabies virus, equine herpesvirus-1, and bovine herpesvirus-1. The
genome is most similar in size and arrangement to equine herpesvirus-1 (185).
Viral transcription occurs in the host cell nucleus. Three classes of mRNA, α
(immediate early), β (early), and γ (late) are transcribed in sequence. The immediate
4

early and early genes encode enzymes and DNA-binding proteins, and the late genes
encode mainly structural proteins. Viral DNA replication occurs in the nucleus and viral
DNA is packaged into capsids within this compartment. The virions acquire their
envelopes by budding from the nuclear membrane (151).
Host/tissue range and cytopathology: FHV-1, unlike other alphaherpesviruses
such as herpes simplex virus type 1 and pseudorabies virus, is restricted in vivo to Felidae
and in vitro to feline cells (34, 35, 82, 111, 172, 175). The virus replicates in cultures of
feline origin including kidney, thymus, tongue, lung (175), cornea (188), tracheal organ
cultures (113), and T-lymphocytes (78), and the virus has been isolated only in feline
cells (35).
FHV-1 grows rapidly in cell culture. Infectious intracellular virus can be detected
six hours post infection, and cell-to-cell spread of virus can be detected six to seven hours
post infection. Extracellular spread of the virus occurs at nine to ten hours post infection,
concurrent with detection of infectious extracellular virus (236).
The characteristic cytopathologic feature of FHV is the occurrence of type A
intranuclear inclusion bodies, which are spherical or oval, acidophilic and separated from
the nuclear membrane by a clear halo (34, 38). FHV also develops multinucleated giant
cells or syncytia in cell cultures, which consist of foci of cells that have lost their distinct
cellular membranes and have fused with adjacent cells. Infected cells are rounded or
elongated in shape and are more retractile than uninfected cells (36).
Antigenic and genomic properties: There is antigenic homogeneity between
isolates from many parts of the world compared to the prototype strain (177). All isolates
belong to one serotype, confirmed by virus neutralization, complement fixation,
5

immunodiffusion, and hemagglutination inhibition assays (175). Minor differences
between strains can be identified with immunoblot and restriction endonuclease analysis.
Some isolates lack a 36 kDa protein, and the restriction enzyme MluI produces variable
restriction patterns among strains, suggesting isolates can be divided into different groups
based on genomic heterogeneity. The importance of these differences in genomes with
regard to virulence is unknown (80, 129). The apparently low rate of variability between
isolates suggests the genome has evolved to a fairly constant state, possibly through an
interaction with the host cell DNA during latency or reflecting some inherent property of
the virus (67).
Viral genes and proteins: FHV-1 contains at least twenty-three viral proteins
(49). Seven FHV-1 glycoproteins have been identified and each share sequence
homology with other alphaherpesvirus glycoproteins. Genes encoding glycoproteins B,
C and H are located in the unique long segment of the genome (125). FHV-1
glycoprotein B homolog was identified in 1992 (126). It is 2829 base pairs and contains
two potential proteolytic cleavage sites (204). In nonreducing conditions, glycoprotein B
in virus infected cells has molecular masses of 143 kDa and 108 kDa, the latter likely
represents the precursor form of the glycoprotein, which lacks glycosylation (79, 126).
Under reduced conditions, glycoprotein B has molecular masses of 100 kDa, 64 kDa, and
58 kDa. Due to the potential cleavage sites in the sequence encoding this gene, the
protein likely consists of a heterodimer or trimer (124). Glycoprotein B is a major
envelope glycoprotein of herpes simplex virus-1 and is crucial for virus infectivity. This
glycoprotein is involved with virus adsorption and penetration and cell-to-cell spread of
the virus by fusion of susceptible cells (126). Glycoprotein B is the most conserved
6

glycoprotein among herpesviruses, and some epitopes of FHV-1 cross-react with herpes
simplex virus-1 antisera (79) and with monoclonals directed against canine herpesvirus
glycoprotein B (118).
The gene for glycoprotein C is 1602 base pairs in length and homologs are nonessential for replication in vitro. Glycoprotein C has molecular masses of 113 kDa and
75 kDa (125). The glycoprotein C of herpes simplex virus type 1 mediates the initial
stage of virus attachment by binding heparan sulfate (133). FHV-1 glycoprotein C has
been demonstrated to bind heparin, indicating the role of FHV-1 glycoprotein C may be
similar to herpes simplex virus glycoprotein C (132). Some FHV-1 isolates have genetic
rearrangements in the glycoprotein C gene, resulting in insertions of repeat sequences,
but the relevance of the rearrangements is unknown (69).
The gene encoding glycoprotein H is the second most highly conserved gene
among herpesviruses. In herpes simplex virus type 1 and pseudorabies virus,
glycoprotein H is implicated in viral entry and direct cell-to-cell spread of virus and in
membrane fusion. This gene is located immediately downstream of the thymidine kinase
gene and is predicted to encode 821 amino acids (127).
Glycoproteins G, D, I, and E have been identified in the unique short segment of
the genome. FHV-1 glycoprotein D has a molecular weight of 53-59 kDa (77, 205). The
FHV-1 glycoprotein D gene appears highly conserved; nucleotide sequences from three
different strains are identical (243). Glycoprotein D has variable functions in different
alphaherpesviruses. Herpes simplex virus type1 glycoprotein D is necessary for virus
growth. Glycoprotein D negative mutants are unable to infect susceptible cells or spread
by direct cell-to-cell transmission. However, glycoprotein D in pseudorabies virus is not
7

essential for virus growth, and varicella-zoster virus lacks a glycoprotein D homolog
(125). The glycoprotein D homolog in FHV-1 has been identified as a hemagglutinin of
feline red blood cells (63, 77, 128). Hemagglutination titers are low (63), but the
hemagglutination activity of FHV-1 is enhanced by treatment of the virus with
polyoxyethylene sorbitan monooleate (Tween 80) and ether, resulting in separation of the
glycoprotein from the envelope of the virus (147).
FHV-1 glycoprotein D may play an important role in the restriction of the host
range of the virus to feline cells (131). FHV-1 does not hemagglutinate dog, chicken, or
guinea pig red blood cells (63). Insect cells expressing FHV-1 glycoprotein D bind only
to feline cell lines, not porcine, bovine, or canine (131). Monoclonal antibodies directed
against glycoprotein D inhibit hemagglutination (79). The hemagglutinins of FHV-1 and
canine herpesvirus share common epitopes. A monoclonal directed against the FHV-1
hemagglutinin inhibits the hemagglutination activity of canine herpesvirus (118).
Glycoprotein E and glycoprotein I form a hetero-oligomeric complex (146) and
are involved in cell-to-cell transmission. The complex is found on the surface of infected
cells and these genes are non-essential for growth in cell culture (125). However, an
FHV-1 mutant containing a disrupted glycoprotein I gene produces a smaller plaque size
than the parent virus (145). Deletion of glycoprotein E and a portion of glycoprotein I
results in reduced virulence when the mutant virus is administered oronasally, suggesting
these are virulence genes (101).
Glycoprotein G is expressed as a secreted protein or is bound to the membrane of
infected cells. It is also a structural protein, incorporated into the viral envelope.
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Glycoprotein G functions as a chemokine binding protein, modulating the anti-viral
chemokine defense system in the host (33).
Glycoproteins B, C and D are also expressed on the surface of infected cells. Cell
membrane fluorescence can be demonstrated at 12 hours post-infection for glycoprotein
C, 16 hours post-infection for glycoprotein D, and 20 hours post-infection for
glycoprotein B. Glycoprotein D has at least four distinct epitopes, glycoprotein C has
two antigenic domains (one neutralizing domain consisting of three overlapping epitopes
and a non-neutralizing domain), and glycoprotein B has only one antigenic site,
consisting of five similar or overlapping epitopes (117). Monoclonal antibodies produced
against these glycoproteins exhibit virus neutralizing activity. The neutralizing activity
against glycoproteins B and C requires complement, but the neutralizing activity against
glycoprotein D shows varying complement requirements. This is possibly due to
recognition of the different epitopes, but the majority of the anti-glycoprotein D
monoclonals neutralize without need for complement (79).
Latency: Like other alphaherpesviruses, FHV-1 establishes latency in the
trigeminal ganglion, as determined by explant /isolation techniques (53, 153) and
polymerase chain reaction (PCR) (181, 218, 237). More than 80% of cats become
latently infected after acute FHV-1 infection, and at least 45% of those shed the virus
(55). The carrier state is characterized by periodic episodes of shedding. Re-excretion of
the virus can be stimulated by stress, such as changes in housing or parturition and
lactation, or induced by injections of steroids (55, 57). The mean lag time between the
induction of stress and re-excretion of virus is seven days, with excretion lasting 1-13
days. Re-excretion may be associated with clinical signs such as mild conjunctivitis or
9

rhinitis or may not be associated with any clinical signs at all (55, 57). Spontaneous
shedding also occurs without an association of clinical signs (55).
Latency associated transcripts are detected in trigeminal ganglia of latently
infected cats (163, 224). These transcripts are the opposite strand of the immediate early
gene of FHV-1 (163), and are considered to indicate a true state of latency when detected
in tissue (211). Other suggested latently infected tissues, determined by detecting nonreplicating virus by PCR, include the olfactory bulbs (56, 181, 218, 237), brain stem
(218), optic nerves (237), and nasal turbinates (181). The virus may also establish
latency in the cornea (181, 224, 237), but latency associated transcripts have not been
detected in the corneas of latently infected cats (224). Isolation of infectious virus from
tissues of latently infected cats is difficult, even from cats actively shedding virus. This
suggests either very little virus is present in the tissues, with few cells infected (163), or
the virus is in a form that is non- infectious (56, 181).
Transmission: FHV-1 has been perpetuated in nature as a result of its ability to
produce latent infections, and latently infected cats represent the most important reservoir
of the virus (55, 166). Herpesvirus is unable to survive outside the host for more than
three days. Samples collected on swabs must be suspended in protein medium to allow
survival up to 72 hours at room temperature. Virus remains viable at room temperature
no more than 18 hours on swabs suspended in saline (176). Direct transmission between
cats and persistence of the virus within cats is necessary for the perpetuation of the virus.
Transmission occurs between shedding and susceptible cats only if there is intimate
contact between them. Widespread airborne transmission does not seem important in
viral spread and FHV-1 is unlikely to be spread between cats by aerosol (58, 173). The
10

virus can be spread by sneezed droplets and the probable effective distance for
transmission is about three feet (177). Spread by fomites is also a mode of transmission
that is more likely to occur in cattery situations (175).
Cats are territorial and do not naturally commingle. This behavior reduces the
contact between cats, decreasing the opportunity to spread respiratory infections.
However, in situations in which cats are brought together from different sources and
housed in close quarters, severe respiratory disease outbreaks may occur (92).
Respiratory disease is most likely to occur in breeding colonies and rescue catteries and
disease is most likely to be detected in younger cats, approximately 4-11 months old (16).
Cats that have recently visited a boarding facility are also most likely to have respiratory
disease (16), and cats in contact with cats outside the household are most likely to have
detectable FHV-1 (219). Poor hygiene within multi-cat households, including breeding
facilities and rescue shelters, is also a risk for upper respiratory tract disease (75).
Upper respiratory infections in cats is second only to overcrowding as the leading
cause of euthanasia in shelters (9). FHV-1 is one of the most important causes of shelter
respiratory disease. In one study, 41% of shelter cats had active FHV-1 infection (9), and
in another study, shedding increased from 4% in cats upon relinquish to 52% after just
one week within the shelter. Though many cases are probably due to recrudescence, this
also represents new cases, suggesting FHV-1 is spread rapidly and efficiently within
shelters (170).
Prevalence: FHV-1 is widespread within the feline population, with at least
70.7% of cats serologically positive (106), but the seroprevalence may be as high as 97%,
based on results from a more sensitive test (42, 140). Prior to the development of
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vaccines, the rate of infection in healthy cats, as determined by isolation from
oropharyngeal swabs, was 1% from household cats and 1.75% from cat show cats.
However, the true rate is likely higher because carriers shed intermittently (235). Recent
studies suggest the rate of carriers, determined by isolation of FHV-1 from conjunctival
swabs (140) and detection of FHV-1 DNA by nested PCR from conjunctival snip
biopsies (213) from clinically normal cats is 10.9% and 12%, respectively. FHV-1 has
been detected in 13.7%-54% of cats with naturally acquired conjunctivitis or respiratory
disease (27, 140, 213).
Clinical disease: The disease produced by FHV-1, designated feline viral
rhinotracheitis (36), is the clinically most significant infection of the feline respiratory
diseases (173). The incubation period is usually 2-4 days (175), but the infecting dose is
a significant factor in determining the length of the incubation period (54). The acute
disease is characterized by pyrexia, salivation, leukocytosis (primarily neutrophilia),
depression, conjunctivitis, serous to mucopurulent ocular and nasal discharge, and
accompanying coughing, sneezing and dyspnea (37, 38, 222). Dendritic corneal ulcers
may also develop but are less common during the acute infection (158), and are
considered pathognomonic if present (160, 183). The most significant lesions are
produced in the upper respiratory tract, especially in the mucosa of nasal passages and
turbinates, as a result of the cytopathic effects of the virus (37). Osteolytic lesions can
occur in nasal turbinate bone (76). The virus has a limited ability to replicate at core
body temperature, so the primary sites of replication are the cooler epithelial surfaces
(211). Thus, the main sites of viral replication are the nasal turbinates, conjunctivae,
tonsils, soft palate, and trachea (37, 38, 56). Experimental infection can be produced by
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application of the virus to the mucosal membranes of the eyes, nose, or mouth, but
disease does not occur with intramuscular injection of the virus (177). Large amounts of
virus are produced and released upon rupture of infected cells. Shedding occurs in all
discharges from the eyes, nose, and throat and infectious virus can be demonstrated in
these secretions for a period of 1-3 weeks after primary infection (175, 177).
Acute infection can occur in kittens, resulting in generalized disease and death
(51, 206). Less common manifestations of FHV-1 include skin ulcers (73, 90), interstitial
pneumonia (120), and lingual ulcers (197). Bronchial pneumonia can develop secondary
to bacterial infection and conjunctivitis can lead to adhesion of the eyelids (82). The
clinical signs may be worse in immunosuppressed cats co-infected with feline leukemia
virus or feline immunodeficiency virus (180, 217). Mortality is high in young or
debilitated cats, but the majority of cats recover in 7-10 days; however, the recovery may
take weeks for severe cases (175).
Abortions have also been associated with FHV-1 infection (76, 206). Herpesvirus
associated abortion in animals is due to viremia, rarely resulting from the spread of the
disease from the lower genital tract. Vaginitis can be experimentally produced by
infecting the vaginal area. Kittens born to queens infected in this manner in the later
stages of gestation have high mortality rates due to generalized infection. Some kittens in
the study were born with respiratory disease, suggesting in utero infection (20).
However, genital tract lesions have not been detected in natural infections (175). Queens
experimentally infected with FHV-1 intravenously or intranasally in the sixth week of
gestation either abort or have dead fetuses. Lesions are detected in the placenta, uterus,
and in a fetus from queens inoculated intravenously, but not in those inoculated
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intranasally (76). In a study evaluating the transmission of the virus, no in utero
infections were demonstrated (58). Therefore, abortions occurring in natural infections
are more likely due to severe maternal infection than to fetal infection with FHV-1.
FHV-1 rarely causes viremia and has a low abortogenic potential, and abortions in
naturally occurring infections are rare (201).
FHV-1 is the only documented viral cause of feline keratits, and corneal
ulceration is primarily seen in adult cats with recrudescence of latent virus. Stromal
keratits is a less common manifestation of FHV-1 infection and results from chronic
recurrent episodes of FHV-1 keratitis. Only a small percentage of cats will have
recurrent bouts of keratitis, but this manifestation of FHV-1 infection is vision
threatening, due to the associated stromal fibrosis and opacification. The mechanism of
stromal disease is unknown, but prolonged absence of corneal epithelium results in
stromal keratitis (6). This may be a function of the duration of the cornea’s exposure to
virus, and after virus gains access to the stroma, keratitis may be mediated by an immune
response to viral antigens with infiltration of infected tissues with neutrophils, followed
by B and T lymphocytes (155). Stromal keratitis does not occur in acute infection unless
cats are treated intraocularly with steroids. Intraocular steroid injections preceding FHV1 infection result in increased severity and prolonged infection with delayed
epithelialization and suppressed collage synthesis, leading to stromal keratitis,
characterized by geographic epithelial ulceration, interstitial edema and deep
vascularization. Other complications include decreased tear production and corneal
sequestration, likely a nonspecific sequelae to significant stromal damage (155, 158).
Recurring FHV-1 ocular disease may be unilateral or bilateral (212).
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FHV-1 DNA has been detected in the corneas of a higher percentage of cats with
eosinophilic keratitis or corneal sequestration than in corneas from clinically normal cats.
Eosinophilic keratitis is a superficial proliferative inflammatory response of the cornea,
predominated by mast cells and eosinophils. Corneal sequestration results from
degeneration of stromal collagen and accumulation of a dark brown or black pigment
presumed to be of tear film origin (156). FHV-1 has also been associated with uveitis.
DNA has been detected in the aqueous humor from cats with uveitis. It is believed FHV1 gains intraocular access via axonal transport along sensory nerve axons from the
trigeminal ganglion, which innervates intraocular structures including the anterior uvea
(139).
FHV-1 may also play a role in chronic rhinosinusitis, but in one study, detection
of FHV-1 DNA was not statistically different in cats with chronic rhinosinusitis versus
control cats. In the study, no actively replicating virus was detected in cats with chronic
rhinosinusitis, so the disease does not appear the result of direct cell lysis (86). However,
increased nasal cytokine expression has been detected in cats with replicating FHV-1,
suggesting FHV-1 does have some role in nasal inflammation (87).
Immunoprophylaxis and immune response: Many attenuated (intranasal (41,
107) and parenteral) vaccines and an inactivated (parenteral) vaccine are available for
FHV-1 in the United States (107). The first documented successful vaccine was the F-2
strain. This was an attenuated vaccine, produced by multiple passages in cell culture,
including some passages at low temperature, and was used intramuscularly. The vaccine,
like all FHV-1 vaccines developed since, produced significant reduction in the disease in
vaccinated cats compared with unvaccinated cats, but it did not prevent disease in all the
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cats tested (21, 22). Vaccination also does not prevent chronic ocular manifestations of
FHV-1 (212). Vaccination does not prevent shedding of virus following challenge, and
according to different studies, it may or may not decrease the course and amount of virus
shedding (31, 107, 166, 195, 222, 238). Vaccination does not prevent the establishment
of a latent infection (165); although, vaccination with at least one strain showed a
reduced latency load in the trigeminal ganglia of cats post challenge (218). This may be
beneficial, because attenuation of the amount of virus that reaches the sensory nerves
results in a smaller reservoir of latent virus from which subsequent reactivations could
arise (109).
Intranasal vaccination may be superior to intramuscular vaccination, requiring one
dose instead of two, and may provide better protection than parenteral vaccines because a
local and or cell mediated immune response may be more important for protection than
serum antibody (41, 166). However, cats shed intranasal vaccine virus (166), and
attenuated intranasal vaccine virus may establish latency (238). Intranasal use of
attenuated parenteral vaccine strains produces severe disease (41, 101, 218).
The use of subunit vaccines may be useful in preventing establishment of a latent
infection with a modified live recombinant vaccine (117). Glycoproteins D and B are
potential targets for subunit vaccines. Glycoprotein D expressing vaccinia recombinants
produced complement-independent virus neutralizing antibodies in immunized rabbits
(205). Also, FHV-1 glycoprotein D expressed in a recombinant baculovirus produced
high virus neutralizing antibody titers in immunized mice (130). Plasmid DNA
expressing glycoprotein B injected into mice also produced virus neutralizing antibodies
(123).
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FHV-1 stimulates a poor immune response. Cats are susceptible to re-infection
six months after primary infection. FHV-1 may evade the immune system. Because it is
highly cell associated, matures intracellularly, and can spread cell to cell without contact
with the interstitium, contact with neutralizing antibody is minimized (8). The immune
response develops with serum neutralizing antibodies appearing about day 16 post
exposure, but antibodies may not be detectable in some cats until three weeks post
exposure (35, 82, 175).
Vaccination does appear to produce long term partial protection from clinical
disease. Vaccination subcutaneously with an inactivated vaccine produced reduced
severity of clinical disease following viral challenge 7.5 years after vaccination in cats.
The vaccine provided persistent antibody titers for three years, and there was a rapid
anamnestic response in the vaccinated cats post-challenge (195). In another study,
vaccination induced a serologic response that lasted at least 48 months (150), and in a
separate study, vaccination provided protection from severe clinical disease 10 and 31
months post vaccination (106). Though detection of FHV-1 antibodies in vaccinated cats
appears to correlate with protection from clinical disease, some cats lacking antibody
titers may also be protected from disease. This suggests the importance of cell mediated
immunity or a rapid anamnestic response to FHV-1 infection (106).
A cell mediated immune response to FHV-1 develops in the cat and can be
demonstrated in vitro. The response is comprised of cytotoxic T cells and antibody
dependent cell mediated cytotoxicity (221, 236). FHV-1 infected cells can also be
destroyed by antibody and complement mediated lysis (236). Protection to FHV-1
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appears to be due to a specific immune response, and local responses are likely to be
involved (31).
Passive immunity in kittens is acquired through colostrum and provides protection
for 5-8 weeks but cannot be correlated with the antibody levels of the queen (58, 177).
Shedding associated with the later stages of lactation, during the time of waning passive
immunity, can result in subsequent infection and clinical disease in kittens (176, 177).
Vaccination of kittens earlier than the recommended age of 9 weeks may be useful in
high risk situations such as in breeding colonies. In one study, a significant portion of six
week old kittens with maternal antibodies responded to parenteral vaccination with a
modified live vaccine (43). In a separate study, vaccination of kittens with an intranasal
vaccine at 5 weeks and a killed vaccine at 5 and 7 weeks also provided protection against
disease in kittens with and without maternal antibodies, though seroconversion was
delayed in kittens with maternal antibodies (89). In some cases, kittens with maternal
antibodies may become subclinically infected from the queen and become latent carriers
of the virus (58).
Diagnosis: Identification of FHV-1 infection has been by detection of FHV-1
antibodies by serum neutralization (178), enzyme linked immunosorbent assay (ELISA)
(42, 191), or hemagglutination inhibition tests (63). ELISA has been shown to be more
sensitive than serum neutralization (42, 191) and hemagglutination inhibition tests (191).
Diagnosis of FHV-1 by serology is problematic. The magnitude of serum neutralization
or ELISA titers is independent of the presence or absence of clinical signs of FHV-1
associated disease, and seroprevalence does not differ between clinically normal cats or
cats with acute respiratory disease or with chronic ocular disease. Detection of serum
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antibodies does not distinguish between infection by wild-type strain or attenuated
vaccine strain. Cats with chronic ocular disease have been shown to have lower serum
ELISA titers than clinically normal cats. Chronic or recrudescent infection, latency, prior
infection, or vaccination may affect titers and limit the usefulness of paired serum
samples for detection of active infection in chronically or latently infected cats (140).
Diagnosis of FHV-1 infection is commonly done by detection of the virus. Cats
shed virus in ocular, nasal, and oropharyngeal secretions for at least 1-3 weeks during the
initial infection, for several days during re-infection, and irregularly during periods of
recrudescence (175). Virus is detected by immunofluorescent antibody tests (28), virus
isolation (38), or PCR (27, 72, 181, 214, 220, 237). Virus may also be detected in tissues
by immunohistochemistry and in situ hybridization (217).
Virus isolation has been considered the gold standard for FHV-1 detection (160).
Virus isolation and immunofluorescent antibody testing may be of limited value in
diagnosing FHV-1 disease in cats with chronic conjunctivitis because cats shed less virus
for a shorter period of time during periods of recrudescence or chronic disease (27), and
virus isolation and immunofluorescent antibody tests have low sensitivity. Positive
results are more likely in cats with disease of shorter duration (159). However, both tests
can detect virus in clinically normal cats (27, 140). In one study, virus isolation was
found to be more sensitive than fluorescent antibody testing for detecting FHV-1 in cases
of chronic conjunctivitis (159), but in a different study, the reverse was found in cats with
chronic ocular disease (140).
Problems exist with virus isolation and immunofluorescent antibody assays.
Interpretation of immunofluorescent antibody assay results is subjective, and nonspecific
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immunofluorescence can be falsely interpreted as positive. Also, staining of the eye with
a fluorescein dye to test for ulcers prior to collecting specimens for fluorescent antibody
testing results in false-positive immunofluorescent antibody results (160). False negative
results may occur with low virus antigen or interference by host derived antibody (27).
Virus isolation requires proper specimen handling to ensure presence of viable virus for
this assay to be successful (140).
There have been numerous PCR assays developed to detect FHV-1 DNA (27, 72,
181, 214, 220, 237). PCR assays have been determined to be more sensitive in detecting
FHV-1 than virus isolation in latently infected cats (181), in cats with acute disease that
have been previously vaccinated (220), and in cats with naturally acquired FHV-1
infection with current signs of conjunctivitis or nasal discharge (27). PCR may be more
sensitive because as previously mentioned, virus isolation requires viable virus, and
enveloped viruses are relatively labile and may be destroyed in transport and with
freezing and thawing of samples. In contrast, DNA is stable and transit time and
temperature appear not to affect the ability to detect FHV-1 DNA in samples (30). Virus
infectivity may also be destroyed by enzymes in saliva or tears. The virions may be
complexed with antibodies, decreasing infectivity, which may explain the increased
sensitivity of PCR in vaccinated cats or in cats with chronic disease. Immature virions
may also give positive PCR results but negative isolation results (181).
Nested PCR has been determined to be more sensitive than single round PCR for
detecting FHV-1 in cats with signs of upper respiratory tract disease (72). Nested PCR is
also more sensitive than virus isolation and fluorescent antibody detection (27, 214).

20

To increase the likelihood of detecting viral DNA in samples from cats with
ocular disease, more than one specimen should be collected. There appears to be no
sampling technique (conjunctival or corneal swabs and scrapings, or biopsies of the
conjunctiva or cornea) that is more likely than another to harvest viral DNA, except in
cats with corneal sequestrum, in which no virus could be detected in swabs (232).
Though more sensitive than isolation, different PCR protocols show marked
variation in sensitivity, which affects the ability to detect FHV-1 DNA. Six published
PCR assays were compared to diagnose FHV-1, and detection rates varied from 29-86%
in cats with keratits and/or conjunctivitis. Each assay also detected five vaccines tested,
suggesting a positive PCR result may be due to detecting a vaccine strain (137).
A more sensitive test may not necessarily be better due to the potential to
increase detection of virus in subclinical shedders. PCR results must be interpreted
carefully, because a positive result may mean FHV-1 is the cause of the disease, found
coincidentally as a result of intermittent shedding, or present secondary to stress caused
by a separate disease that is primarily responsible for the clinical signs (27, 137).
In one of the PCR studies, FHV-1 DNA was detected in samples from 31% of
clinically normal shelter cats. The author suggests PCR may be of limited value for
diagnosing FHV-1 disease due to detection of healthy carriers (27). In an additional
study, FHV-1 DNA was also detected in 6/13 keratectomy specimens from clinically
normal shelter cats (213), and in another study, FHV-1 DNA was detected in 45/92
corneas from cats without a recent history of respiratory or ocular disease. Twenty-nine
of the positive samples were obtained from shelter cats. The high rate of detection of
FHV-1 DNA in normal corneal samples may represent detection of latent infection,
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because the cornea may be a latently infected tissue, or may represent detection of
subclinical shedders (224). Each of these studies used shelter cats as the clinically
healthy control groups, which may have exaggerated the problem of detecting subclinical
shedders, because as previously mentioned, cats in that environment are at an increased
risk of being exposed to the virus or having reactivated virus (27).
Real time PCR assays have also been developed for detection of FHV-1 DNA and
are more sensitive than virus isolation (74, 231). Real time PCR and isolation results
correlate well in the acute phase of the disease, but real time PCR is more likely to detect
FHV-1 DNA in later phases of disease in which there is a marked decline of virus titer
(231). Real time PCR has an advantage over conventional PCR because of the ability to
determine viral load and track the course of disease. Real time PCR is also less prone to
contamination than conventional PCR due to the lack of post-amplification processing
(231). This is especially true for nested PCR, in which contamination from the original
product can arise (214).
Antiviral drugs: There are currently no anti-herpetic drugs approved for
veterinary use in the United States, but many antiviral drugs marketed for treatment of
herpes simplex virus type 1 infections in humans have been explored as therapeutic
agents for treatment of FHV-1 infections in cats (136). Several acyclic nucleoside
analogs have been tested, including acyclovir, ganciclovir, and penciclovir (136, 157).
These drugs work by incorporating into the viral DNA chain, terminating its growth and
inactivating viral DNA synthesis. Acyclic nucleoside analogs require three
phosphorylation steps to be converted to their active form, and the first step is performed
by the viral thymidine kinase, giving these drugs specificity for virally infected cells and
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making them relatively safe (136). Acyclovir is relatively ineffective against FHV-1 in
vitro (136, 157, 228), but it appears to be effective in cats for treatment of FHV-1 related
conjunctivitis and corneal ulcers if administered topically several times a day (244).
Ganciclovir and penciclovir show greater efficacy than acyclovir in vitro, but in vivo
studies have not been performed (136, 228).
Other types of antiviral drugs have also been tested. Ribavirin, an inhibitor of
nucleic acid synthesis, has only a slight antiviral effect on FHV-1 and reduces the rate of
cell proliferation in treated cultures (174). Foscarnet, a drug that inhibits DNA
polymerase by interacting with the pyrophosphate binding site of the enzyme, has
intermediate to low antiviral efficacy in vitro (135, 228), but another viral DNA
polymerase inhibitor, PMEDAP, has potent FHV-1 inhibition in vitro (228). Cidofovir, a
cytosine analog, has been shown to be effective against FHV-1 in both CRFK cells (136,
228) and feline primary corneal cells (189). Cidofovir does not require phosphorylation
by the viral kinase, and it inhibits the viral DNA polymerase 1000 times more potently
than it inhibits the host cell polymerase (136). However, cidofovir causes increased cell
death and decreased cell proliferation in corneal cells at effective antiviral doses (189).
The antiviral drugs that have shown the greatest effectiveness in vitro include
idoxuridine and trifluridine (135, 157). These compounds also have non selective
antiviral activity and inhibit CRFK cell proliferation at effective antiviral doses (157).
The antivirals are epitheliotoxic and chronic use may lead to corneal or conjunctival
disease (157), or may reduce cellular proliferation enough to negatively affect healing of
corneal lesions (189). An additional problem with the current antiviral drugs is that these
drugs are virostatic and not virocidal. Therefore, to be effective, these drugs must be
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applied 4-6 times a day. Idoxuridine, vidarabine, and trifluridine have been used
clinically as topical treatments for ocular lesions, but one study suggests that the overall
response to these treatments is poor. This is possibly due in part to the need for frequent
application of the drugs to be effective and poor owner compliance (212).
There is currently no effective systemic antiviral drug available for use in cats
(210). Acyclovir is the only systemic drug that has been adequately tested and has been
used clinically for treatment of FHV-1, but it has limited efficacy due to poor
bioavailability and may also produce toxic side effects in cats (135, 167). Because of the
poor bioavailability of acyclovir, a pro-drug of acyclovir, valacyclovir, has been tested in
cats. After oral administration, valacyclovir is almost completely converted to acyclovir
and provides much higher plasma concentrations of acyclovir than obtained with oral
acyclovir administration. Despite achieving effective doses in cats in the study, this drug
did not suppress FHV-1 replication in the acutely infected cats and was found to be toxic,
causing hepatic and renal necrosis and severe bone marrow suppression (154).
Idoxuridine has also been tested systemically for treatment of FHV-1 in cats, and it
produced vomiting, depression, and loss of appetite when administered intraperitoneally
(208). Therefore, any currently available systemic antiviral drug must be used with
caution in cats (154).
Adjunctive therapies: There are also adjunctive therapies for chronic FHV-1
infections. Oral lysine supplementation is used clinically to treat FHV-1 infected cats.
Oral L-lysine supplementation reduces the severity of conjunctivitis in cats undergoing
primary infection (215), and reduces viral shedding in latently infected cats following
changes in husbandry and housing but not following corticosteroid administration (141).
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In vitro, reduction of FHV-1 replication by lysine supplementation only results with
reduction of arginine concentrations. Arginine exerts a substantial growth-promoting
effect on FHV-1 and is an essential amino acid for viral protein synthesis, and it appears
lysine antagonizes this effect. Lysine and arginine competitively inhibit transport of each
other by using a common transport system, and lysine induces arginase, an enzyme that
causes the degradation of arginine. Arginine deficiency inhibits synthesis of infectious
viral particles and down regulates synthesis of viral proteins (138).
Human recombinant interferon alpha has also been used as a treatment for FHV1. Oral administration of low doses has been associated with reduced clinical signs but
not reduced FHV-1 shedding (134). The antiviral effect in vitro is modest (190) and dose
dependent (198). Interferon treatment may only be effective when administered in high
doses early in the course of infection. Human recombinant alpha-2b interferon is less
effective against FHV-1 than feline recombinant omega interferon in vitro. Interferon is
probably most effective when administered as an adjunct treatment (198). When used in
combination with human recombinant interferon alpha, acyclovir could be used at a
nearly eight fold reduction to achieve maximal inhibition of FHV-1 in vitro, and
synergistic interactions were seen between the two treatments (239).
Additional therapies that have been tested for FHV-1 infection include bovine
lactoferrin and cat-mouse chimeric antibodies. Bovine lactoferrin is a mammalian ironbinding glycoprotein that is produced by mucosal epithelial cells and found in secretions
including milk, colostrums, saliva, and tears. It has antiviral, antibacterial, and
antimycotic properties. It appears to inhibit FHV-1 attachment or penetration into cells
and has an inhibitory effect on FHV-1 replication in CRFK cells (12).
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Mouse-cat chimeric antibodies targeting FHV-1 glycoprotein D have been used in
two separate studies (226, 227). In one study, the antibodies were administered
intravenously to cats on day 2 post-infection with FHV-1. The treated cats had decreased
clinical signs compared to the control cats (226). In the second study, the antibodies
were used prophylactically, administered subcutaneously 15 days prior to infection with
FHV-1, and resulted in decrease clinical signs in the treated group (227).
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RNA Interference Literature Review
Currently, there is no effective therapy that specifically targets FHV-1.
Vaccination against FHV-1 provides only partial protection from clinical disease (195),
and antivirals are minimally effective (212). Therefore, the development of a therapy to
specifically target this virus to decrease clinical signs associated with acute infections, to
decrease establishment of latent infections, or to prevent recrudescence in latently
infected cats to prevent viral shedding should be explored. Such a therapy would be
useful for cats in shelters, catteries, or multiple cat households, environments which are
known to be associated with an increased risk for FHV-1 infection (75).
Recently, RNA interference (RNAi) has been shown to be a possible therapeutic
method for viral infections. RNA interference therapy is sequence specific posttranscriptional gene silencing based on an ancient self-defense mechanism conserved in
many eukaryotic species (64).
Discovery: Silencing based on sequence homology was first discovered in
transgenic plants and fungi. In 1990, in a study in petunias, attempts to over-express
endogenous genes by introduction of additional copies (transgenes) resulted in
suppression of endogenous gene expression as well as the transgenes (152). In a study in
1993, infection by an RNA virus was shown to be restricted in plants by artificial
expression of one of the viral genes, an observation apparently mediated by cytoplasmic
activity that targets specific RNA for inactivation (119). In 1996, quelling (transgene
induced gene silencing) in Neurospora crassa, was determined to be mediated by an
RNA molecule, and silencing was discovered to be associated with a decrease in
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messenger RNA (mRNA) from the silenced gene (32). The breakthrough discovery
occurred in the nematode, Caenorhabditis elegans, in 1998, in which this process of posttranscriptional silencing was linked with double-stranded RNA (dsRNA), and the process
was named RNA interference (50).
Cellular machinery and mechanism: Introduction of dsRNA into cells can
specifically lead to the degradation of mRNAs containing homologous sequences,
resulting in gene silencing (50, 194). RNA interference is initiated by a member of the
RNase III family of ATP-dependent ribonucleases called Dicer, which binds with high
affinity to double-stranded RNA and chops it into 21-23 nt. small interfering RNA
(siRNA) duplexes, containing 19 base-pairs and 2 nucleotide 3’ overhangs (14, 48). The
siRNA duplexes, containing 3’ phosphates and 5’ hydroxyls, are incorporated into the
RNA induced silencing complex (RISC) (71, 179). For each duplex, one strand becomes
the guide strand, and the other becomes the passenger strand. The strand of the duplex
that has the 5’ end less tightly bound to its complement becomes the guide strand (95,
194). The endonuclease component of RISC, Argonaute, cleaves the passenger strand,
and it is removed from the complex, activating RISC, which contains the single-stranded
guide (143, 179). RISC then targets homologous mRNA transcripts by base pairing with
the guide strand and cleaves the messenger RNA (performed by the Argonaute protein).
The mRNA is cleaved between bases 10 and 11 relative to the 5’ end of the siRNA guide
strand (48). The mRNA is further degraded by exonucleases (70, 98).
Amplification of the silencing signal and systemic spread of silencing occurs in
plants and C. elegans, but this phenomenon has not yet been demonstrated in mammals
(11). In addition to the primary RNAi response, in which double stranded RNA interacts
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with Dicer, resulting in 21-nt dsRNAs that interact with RISC to target complementary
mRNA sequences, in plants and C. elegans, amplification of the trigger RNA occurs.
The amplification contributes to the potency and persistence of RNAi in these organisms.
Secondary siRNAs are produced in C. elegans and in the plant Arabidopsis by RNA
dependent RNA polymerase (RdRP), which copies the mature mRNA template (11).
These secondary siRNAs in C. elegans are 21-22 nt in length and have triphosphate 5’
termini, unlike primary siRNAs, which have a monophosphate at the 5’ end. It is
assumed in C. elegans that primary siRNAs act as guides to recruit the RdRP to the nondegraded target transcript, resulting in the unprimed synthesis of short antisense RNAs,
mainly upstream from the targeted sequence but also downstream, which are removed
from the target transcript and incorporated into complexes capable of finding additional
targets (168, 199). Currently, there have not been any RdRP genes discovered in
mammalian genomes (11).
RNAi in mammalian cells and the interferon response: Long dsRNAs activate
RNAi in C. elegans (50) and in fruit flies, Drosophila melanogaster (71), but initial
attempts to activate RNAi in mammalian cells with long dsRNAs failed. dsRNA larger
than 30 base pairs in the cytoplasm of mammalian cells can trigger the interferon
response (47). However, after the discovery that RNAs 21-22 nucleotides in length
mediate RNA interference (48), the use of synthetic 21 nucleotide (nt) siRNAs was
demonstrated to induce RNAi in mammalian cells without inducing interferon (47).
Interferons are cytokines that function as the host’s first line of defense against
viral infections and are part of the mammalian innate immune response. Type 1
interferons (alpha and beta) are produced in response to dsRNA (common viral
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replication intermediates). dsRNA binds and activates dsRNA-activated protein kinase
PKR and 2’, 5’-oligoadenylate synthetase. Activated PKR halts translation by
phosphorylation of translation initiation factor eIF2α (eukaryotic initiation factor subunit
α), resulting in a general inhibition of cellular protein synthesis. Activated 2’-5’oligoadenylate synthetase causes mRNA degradation by activating RNase L in a non
sequence specific manner (47). Interferon alpha is primarily produced by leukocytes, and
interferon beta is produced by fibroblasts and epithelial cells. The role of interferon
induction is to induce antiviral, antiproliferative, and immunomodulatory activities in
cells (207).
RNAi as an antiviral defense mechanism: RNAi is an innate antiviral defense
mechanism in plants (39) and Drosophila (233). The dsRNA develop as a result of
replication intermediates or from secondary structure of viral RNA or from DNA viruses
by annealing of overlapping complementary transcripts produced by symmetrical
transcription (5). An antiviral role for the RNAi machinery appears to also exist in C.
elegans. Though no natural virus of C. elegans is known, experimental infection with
vesicular stomatitis virus results in resistance to the viral infection in the nematode (192,
242). It is unclear if RNAi is a natural defense mechanism against viruses in mammalian
cells. Because long dsRNA viral replication intermediates appear to be the natural
precursors for siRNAs, and long dsRNA induces interferon and general shutdown of
transcription in mammalian cells, it is unknown how this process may be naturally
activated by viruses in mammalian cells (39, 64). Mammals have also developed a
highly sophisticated acquired immune system based on protein recognition that protects
against infection in a highly specific manner (64).
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miRNA pathway: Naturally occurring siRNAs have not yet been detected in
mammalian cells (64). However, related small RNAs, called microRNAs (miRNA) have
been discovered in mammalian cells (108, 112). miRNAs result from endogenous noncoding genes distinct from the mRNA they control or come from introns of pre-mRNAs
(10). miRNAs were first discovered in C. elegans (108, 112), and have also been
identified in fish, worms, flies, and plants and are generally conserved. miRNAs are
expressed during developmental stages and in a tissue specific manner and have
important regulatory roles for development and differentiation in plants and animals (10).
Long primary transcripts (pri-miRNA) are cleaved by an RNase III endonuclease,
Drosha, in the nucleus, resulting in 60-70 nucleotide stem loop precursors (pre-miRNA).
The pre-miRNAs are transported from the nucleus by the export factor, Exportin-5. In
the cytoplasm, the pre-miRNAs are processed by Dicer into approximately 22
nucleotides. miRNAs are then incorporated into RISC and regulate mRNA expression by
either target destruction or translation inhibition. Partially complementary sequences,
predominately in the 3’ untranslated region of the target, result in blockage of translation.
Complementary results in destruction of the target by RISC, which mainly occurs in
plants (10). Apparently siRNAs and miRNAs program RISC equivalently and can have
the same effects on mRNA expression, despite different origins (251).
RNAi in human cells likely results from incorporation of siRNAs into the miRNA
pathway (70). While Drosophila has two Dicer proteins, humans have only one Dicer
protein. In Drosophila, miRNA and siRNA pathways use separate Dicer proteins. The
Dicer protein in human cells resembles the DICER-1 protein in Drosophila, essential for
miRNA processing. Also, the Argonaute proteins of mammalian cells are related to
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Drosophila Ago1, which preferentially binds miRNAs. Mammalian cells lack a homolog
of Drosophila Ago2, which preferentially binds siRNAs and protects Drosophila from
infection with RNA viruses (52, 70). This suggests the human genome has retained the
miRNA processing machinery, but not the specific machinery for processing long
double-stranded RNAs (70).
Viral suppressors of RNAi: If RNAi is a natural defense mechanism against
viruses in mammals, then viral infection should result in the production of siRNAs of
viral origin, but as previously stated, no naturally occurring siRNAs have been identified
in mammalian cells. Also, inhibition of RNAi should result in increased viral replication,
and as an adaptive response, the viruses should have developed proteins that inhibit the
RNAi response. Each of these criteria has been demonstrated in plants, in which RNAi is
an important viral defense mechanism. In an attempt to prove RNAi is a naturally
occurring process in mammalian cells, recent studies have attempted to identify RNAi
suppressors in mammalian viruses. In nature, the best examples of viral suppressors of
RNA interference are found in plant viruses (39).
RNAi suppressor dsRNA binding appears to be a key element in the silencing
suppression strategy that has evolved independently many times. Many unrelated plant
RNA virus RNAi suppressors bind dsRNA. Many of these suppressors are size selective,
preferentially binding 21 nucleotide dsRNA. This is the fragment size generated by
Dicer, so expression of a protein that binds these RNAs, preventing their incorporation
into RISC to form active silencing effecter complexes, is an ideal viral defense strategy.
This may also be true for invertebrate virus RNAi suppressors, such as the flock house
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virus B2 suppressor, also a double stranded RNA binding protein, which could
potentially inhibit viral suppression by RNAi in C. elegans (144).
dsRNA binding proteins have been the target of investigation for potential human
virus silencers of RNAi. Two such proteins, the non-structural (NS1) protein of
influenza A and the E3L protein of vaccinia have been shown to suppress RNAi in
experiments in Drosophila cells (115). NS1 was shown to bind siRNAs in a plant
experiment, suggesting it suppresses RNAi by sequestering siRNAs, a mechanism which
occurs in many plants (25). But it has been discovered that influenza NS1 does not
suppress RNAi in mammalian cells, though it does inhibit the interferon response (100).
Both NS1 and E3L are important for the pathogenesis of these viruses in the natural host
because they function as inhibitors of the innate antiviral response regulated by
interferon. So the suppression of RNAi by these proteins is likely due to their overexpression in cells not naturally infected with these viruses and to their ability to bind
dsRNA (39). Interestingly, a size specific dsRNA binding virus silencing suppressor has
not yet been identified in animals (144).
A suppressor of RNAi has also been proposed for HIV-1. The gene Tat encodes
an activator of the HIV-1 LTR, and according to some researchers, Tat inhibits Dicer.
Therefore, siRNAs cannot be produced and viral RNAs are not targeted (13). However,
Tat can also act as a nonspecific dsRNA binding protein and the observed effect is
probably due to the massive over-expression of the protein. At physiological
concentrations, the protein shows no inhibition of RNAi (39).
Human adenovirus type 5 encodes two non-translated RNA polymerase III
transcripts, which act as decoy RNA to prevent the induction of the interferon system in
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infected cells. The virus associated (VA) RNAs also appear to inhibit RNAi by acting as
competitive substrates for Dicer and are processed into 21nt dsRNAs that are
incorporated into RISC. These siRNAs may act more like miRNAs to suppress viral or
cellular gene expression during infection (5). VA1 was also shown to compete with
cellular pre-miRNAs for transport from the nucleus by the factor Exportin-5 (121). VA1
RNA is highly expressed during viral infection, so the inhibitory effect of this RNA could
be inadvertent. Its activity as an RNAi inhibitor may be coincidental based on its
structure, which resembles pre-microRNAs. It is unknown if VA RNA specifically
evolved to function as an RNAi inhibitor (39).
Cellular miRNA may have a role in antiviral defense in mammalian cells. Human
miR-32 inhibits primate foamy virus type 1 in human cells as the result of “fortuitous”
near perfect sequence homology between a portion of the virus sequence and the cellular
miRNA. The homology is adequate enough to produce virus translation inhibition. Also,
the virus produces a protein, Tas, that inhibits the miR-32 translational inhibition, in a
non-sequence specific manner (110). However, it remains unclear whether Tas does
indeed act as an RNAi suppressor in primate foamy virus infected cells (39).
Experimentally induced antiviral RNAi in mammalian cells: The RNAi
machinery likely exists in vertebrates only for post-transcriptional regulation by genome
encoded miRNA. Despite this fact, the machinery can be reprogrammed for antiviral
immunity by the introduction of exogenous RNA to generate an artificial RNAi response
(39). Numerous experiments demonstrate that exogenous siRNAs can prevent in vitro
and in vivo infections with many different viruses, including positive and negative
stranded RNA viruses, retroviruses, and DNA viruses (64).
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RNA silencing could be used to complement the protein-based immune response
to viruses. RNAi occurs in the cytoplasm of cells, where recognition of virus by B and T
lymphocytes cannot take place. The RNAi response is rapid, taking only hours to exert
its effect; whereas, the immune response, even the anamnestic response, takes days (29).
In cases in which virus causes severe acute disease due to significant cytopathic effect
resulting from high multiplicity of infection, low immunogenicity, high replication
capacity, direct toxic effects, or a combination of each, RNAi could support or enhance
the antiviral effects for a short period of time until innate or adaptive immune responses
allow the host to overcome the pathogen (94).
Incoming positive-stranded viral RNA may be targeted by RNAi, as is the case
for West Nile virus (62) and hepatitis C virus (247). These viruses initially act as mRNA
after infecting cells, and the viral target of the RNAi machinery is likely the mRNA
(strand that directs protein synthesis) and not viral genomic RNAs (strands acting as
templates for replication) (7, 18, 61). This is demonstrated by the superiority of RNAi
targeting the positive-strand of a positive single-stranded RNA virus, versus targeting the
negative strand replication intermediate (193). Genomic strands kept inside specialized
compartments in the cell cytoplasm, such as occurs with rotavirus (7) and West Nile virus
(62), are likely inaccessible to the RNAi machinery.
Various phases of the life cycle of viruses have been targeted by RNA
interference. Targeting viral transcription factors, such as E6 in the human
papillomavirus, results in an inhibition of viral gene expression and inhibited growth in
culture (94). Targeting a portion of the influenza RNA transcriptase effectively inhibits
production of all viral mRNAs (61). Targeting the 5’ untranslated region of hepatitis C
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virus, which has an internal ribosomal entry site for translation of the entire viral
polyprotein, inhibits protein synthesis. Blocking synthesis of non-structural proteins
required for replication of subgenomic viral RNA results in suppression of viral infection
(250).
Inhibiting viral replication is likely the best method of suppressing viral infection
(94). In many studies, the RNA dependent RNA polymerase of RNA viruses, including
SARS (234), West Nile virus (164), and coxsackievirus B3/picornavirus (193) has been
targeted to inhibit viral infection. Virus encoded DNA polymerase is also an effective
target for inhibiting viral replication of DNA viruses such as herpesviruses (241). Also,
silencing of the nucleocapsid gene, which produces a protein necessary for genome RNA
replication, has been shown to inhibit influenza replication in vitro and in embryonated
chicken eggs (61).
Attachment proteins have also been targeted effectively, including the spike
protein of SARS (2), and the envelope glycoprotein B of herpes simplex virus type 2
(169). Silencing the attachment protein VP4 of rotavirus has been shown to be effective
in reducing infectious viral progeny, whereas all other structural proteins were unaltered
(45).
Also, RNAi can be used to target genes whose products are involved in assembly
and budding of the virus particle from the plasma membrane. In a study with the Sendai
virus, a member of the Paramyxoviridae family, targeting of the matrix protein resulted
in reduction of virus production, but had no effect on viral replication or transcription
(149). Knockdown of viral genes used in late stages of the intercellular viral life cycle,
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such as for viral assembly, is expected to be less effective than RNAi in early steps of the
viral life cycle (94).
Down regulation of cellular factors associated with viral infections has proven
effective for inhibiting replication of HIV-1. However, many molecules are essential for
normal cell processes and are inappropriate targets (94).
Methods of siRNA delivery into cells: Effective therapeutic use of siRNAs
involves the development of delivery systems that stabilize the siRNAs but not interfere
with their gene silencing activity, provide efficient delivery to the target organs, and
maintain a siRNA half life sufficient enough to be therapeutic (1). Currently, cationic
lipids and polymers are commonly used to transfect cells in vitro. However, problems
associated with these methods include lack of transfection efficiency and toxicity. A
commonly used transfection reagent, Lipofectamine 2000, by itself and complexed with
siRNAs is toxic to cells at the doses required for optimal transfection, and use of high
concentrations of siRNA results in cellular detachment (203). However, lipid
transfecting reagents have been used successfully in in vivo studies (169) (19).
Polyethylenimine (PEI), a synthetic polymer containing a high cationic charge,
has been used in many studies. PEI is able to complex negatively charged siRNAs,
forming colloidal particles which are endocytosed by the cell. The buffering capacity of
PEI protects the siRNAs from destruction within the endosomes and the effects of the
PEI result in osmotic swelling and disruption of the endosomes, with release of the
complexes (1). PEI has been effectively used to deliver influenza virus gene specific
siRNAs into lung cells by intravenous administration for therapeutic/prophylactic
treatment of influenza in mice (60). But in other studies, PEI used intranasally resulted in
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sickness and death in mice (19), and when used intratracheally or intravenously, resulted
in severe lung inflammation in mice (114).
Additional methods of delivery to increase transfection efficiency have been
studied, including using cell-penetrating peptides, which interact with negatively charged
particles on the cell surface and appear to be taken into the cell by endocytosis. The
problem with transfection efficiency may not be inefficient uptake of molecules, but the
lack of release of bioavailable siRNA molecules from endocytosed vesicles (230).
Early in vivo studies used hydrodynamic intravenous injection to force siRNAs
into cells. However, this is impractical for use in humans, because it may cause transient
right sided heart failure and liver damage by requiring injection of a bolus of liquid
equivalent to 3 liters (59). Transfection is good for local delivery of siRNAs, especially
for delivery to mucosal surfaces (19, 169). In fact, local delivery of naked siRNAs in cell
culture medium (19) or in a dextrose solution (114) into the nasal cavity has been
successful for prevention/treatment of respiratory syncytial virus (RSV) in mice and
SARS in macaques. Currently, siRNAs delivered by aerosol administration are being
used in a phase I clinical trial for RSV (98). However, systemic delivery is more of a
challenge. Ideally, the goal is to deliver siRNAs into specific cells to decrease the
amount of drug necessary for therapeutic effect and avoid nonspecific silencing in
bystander cells. A method for targeted delivery is antibody mediated delivery. The Fab
fragment directed against the HIV-1 envelope protein gp160, fused to siRNAs, has been
used to deliver siRNAs specifically to cells expressing the HIV-1 envelope protein. This
method was successful for targeted delivery both in vitro, and in vivo, when injected
intravenously in mice (202).
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Down regulation of target genes with siRNAs is transient because intracellular
concentrations are diluted over consecutive cell divisions (98). The effect lasts only 3-5
days in cell culture. This duration of silencing is acceptable for acute infections such as
SARS and influenza, but not for chronic infections such as HIV and hepatitis C (94).
Silencing can be enhanced by consecutive applications of siRNAs to virus infected cells;
however, this can lead to selection of mutants that have changes in the target region
(247), especially in chronic infections with RNA viruses that produce quasispecies
populations (104).
Stable expression of RNA effector molecules is possible with plasmids or viral
vectors. The most common approach uses short hairpin RNAs (shRNAs), which are
generated from DNA vectors that express the short hairpin structures, resembling premiRNA, from RNA polymerase III promoters (4, 24). Polymerase II promoters have also
been used to produce shRNAs that mimic pri-miRNAs (98). The short hairpin structures
are processed into siRNAs by Dicer (24). In Drosophila, Dicer has been shown to be
instrumental in handing over the 21 nucleotide duplexes to RISC, and Dicer substrates,
such as shRNAs, are more potent inducers of RNAi than 21mer siRNAs (4). The
shRNAs are incorporated into the miRNA pathway, and over expression of shRNAs in
vivo can be fatal. In one study, shRNAs expressed from a viral vector in mouse liver
cells resulted in liver failure and death in the mice. There was associated down
regulation of liver miRNAs, presumably due to the competition of the cellular miRNAs
with the shRNAs for cellular components of the miRNA pathway, including the nuclear
factor exportin-5 (68).
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Dicer substrates incorporated into the miRNA pathway beyond the nuclear
processing stages may potentially be safer for use in vivo. Recently, longer siRNAs, 27mers, were also shown to be more potent inducers of RNAi. These longer siRNAs are
processed by Dicer and therefore, the resultant siRNAs are more efficiently incorporated
into RISC (96).
Viral vectors, such as lentivirus or adenovirus vectors, have been used extensively
in vitro to deliver shRNA plasmids into cells for long term expression of RNA effector
molecules. These vectors are currently the best vehicles for effective transfer of genetic
material into cells (223). Problems with viral vectors used in the past in vivo for gene
therapy have included a massive immune response to an adenoviral vector that had
disseminated into the circulation of a patient, and oncogenesis (leukemia) in patients by a
retrovirus vector that inserted in or near an oncogene. However, improvements have
been made in these viral vectors (223). In fact, in an upcoming clinical trial, a lentiviral
vector will be used to deliver a shRNA targeting HIV-1 into hematopoetic stem cells ex
vivo as part of a combinatorial RNA therapy for HIV-1 infection (98).
Toxicity associated with experimental RNAi: Design of siRNAs may be more
important for effective targeting than the method of delivery. The thermodynamic
properties of siRNA molecules are critical to the functionality of the molecules. These
properties facilitate association with RISC and subsequent degradation of target mRNA
(95).
siRNAs must be designed to prevent off-target effects, which are toxic to the cell.
Off-target effects associated with synthetic siRNAs have been shown to be concentration
dependent, with increased concentrations of siRNA leading to a stress response within
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the cell. The effects may include stimulation and suppression of expression of genes
unrelated to the intended target (171, 196). These effects appear to be sequence-related;
siRNAs may cross-react with mRNAs of limited sequence homogeneity. As few as 11
contiguous nucleotides of sequence homogeneity, specifically located in the 5’ end of the
antisense strand, are capable of cross-hybridizing to transcripts of non-targeted genes,
resulting in their silencing. Both the sense and antisense strands are capable of causing
off-target effects (83). Thus, siRNAs should be designed to direct the antisense strand
(mRNA complement) into RISC (85). In a more recent study, off-target effects were
shown to result from homology between sequences of 7-8 nucleotides in the 5’ end of the
antisense strand and the 3’ untranslated region of the unintended mRNA targets. Thus,
the off-target silencing occurs in a manner similar to silencing by miRNAs (84).
Scrambled siRNAs used as controls may translationally suppress untargeted genes by
forming bulging loops and initiate the miRNA mechanism. In functioning like miRNAs
with partial homology, mRNA levels of off-target genes may be unaffected, but protein
expression is decreased (84). Considering as few as seven nucleotides of homogeneity
are all that is necessary to potentially produce off-target effects, specificity in siRNA
design is difficult to achieve, and it is unlikely that all off-target effects can be prevented
(84). Therefore, observing the same phenotype with multiple individual siRNAs
targeting the same gene increases the confidence that the knockdown of the intended
gene can be attributed to the observed phenotype (84, 85).
Toxicity may also be due to activation of the innate immune response by siRNAs.
Long dsRNA is detected in vertebrate cells by the dsRNA-activated protein kinase PKR
and by Toll-like receptor 3. Therefore, as previously mentioned, long dsRNAs cannot be
41

used as triggers for the RNAi response in mammalian cells, but short siRNAs can be used
successfully (47). However, production of siRNAs with a bacteriophage T7 RNA
polymerase induces a type 1 interferon response. The response has been shown to result
from a 5’ triphosphate on the siRNAs, which is used by the polymerase to initiate
transcription (97). shRNA plasmid vectors have also been shown to trigger an interferon
response. The authors suggest the response may be due to the accumulation of
unprocessed polymerase III transcripts that trigger interferon expression, so the lowest
effective dose of vector must be used to alleviate the problem (23).
Therefore, chemically synthesized siRNAs represent the gold standard for RNAi
applications (4). However, one report suggests 21 nucleotide dsRNAs (including
chemically produced siRNAs) transfected into cells can activate PKR in a concentration
dependent manner, resulting in interferon beta production and nonspecific suppression in
cells (200). A different study suggests siRNAs mediate a type 1 interferon response by
binding Toll-like receptor 3, which recognizes dsRNA and induces interferon (93).
However, use of naked siRNAs in vivo is not associated with much of an interferon
response, but when coupled with cationic lipids, a marked interferon (type I and II)
response can be generated (122). In two additional studies, siRNAs delivered by lipid
transfection reagents induced production of interferon alpha in plasmacytoid dendritic
cells in vitro and production of interferon alpha and cytokines, IL-6 and TNFα, with
activation of T cells and dendritic cells in the spleens of mice (81, 91). It appears siRNA
activation of the innate immune response is dependent on the use of delivery vehicles and
the recognition of the siRNAs occurs within the endosomal pathway by toll-like receptor
7, which is located in the endosomal membrane and recognizes single-stranded RNA
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(81). Therefore, PKR and Toll-like receptor 3, binders of long dsRNA, likely do not
represent the major mechanisms by which siRNAs are detected by the innate immune
system (81). The activation of Toll-like receptor 7 is dose dependent and sequence
dependent. Poly (U) or GU rich sequences can be immunostimulatory, and siRNAs
containing a UGUGU motif or a GUCCUUCAA motif have been determined to activate
the innate immune response (81, 91). Therefore, testing for interferon induction is
important before attributing knockdown of gene expression to RNAi in mammalian cells
(23).
siRNA design: Many siRNA design criteria have been developed to increase the
effectiveness of individual siRNAs and to augment the production of toxicity due to offtarget effects, activation of the innate interferon response, or some nonspecific effect.
The most important criterion appears to be asymmetry in the stability of the duplex ends.
The 5’ end of the antisense strand should be less thermodynamically stable than the 3’
end (3, 182) This facilitates the use of the antisense strand as the guide strand by RISC
(95, 194). The A/U differential of the 3 terminal base pairs at either end of the duplex is
important for this asymmetry (3). The 5’ end of the antisense strand should be A/U rich,
especially the first five nucleotides (182, 225). According to evaluations of siRNAs,
functional siRNAs (defined as producing 70% or greater knockdown of the intended
mRNA target (3)) have an A/U at position 1 of the antisense strand, but no G/C, and have
a G/C at position 19 of the antisense strand, but no U (3, 182, 225). Other single
nucleotide bases associated with effective silencing include an A at positions 17 and 14, a
U at position 10, and no G at position 7 of the antisense strand (3, 182). Additional
recommendations include, a G/C content of approximately 30-53% (3, 182), with absence
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of a long G/C stretch of more than 9 nt in length (225), a low melting temperature, and
lack of inverted repeats which would lead to hairpin structures in the antisense strand
(182). The 3’ overhangs have little to no effect on the activity (3). Despite using rational
design rules, it is still difficult to predict if a particular siRNA will work. It is expect
about 1 out of every 3 siRNAs will give highly effective silencing (66), and some siRNA
that should not work according to the design rules are sometimes the most effective (19).
Viral RNAi escape mechanisms: The mRNA secondary structure also
determines siRNA silencing efficiency (103, 240). This was demonstrated in an HIV
study in which a point mutation outside the siRNA target sequence resulted in changes in
the secondary structure of the mRNA. The mutation caused the target sequence to be
incorporated into a hairpin structure, thereby inhibiting its ability to base-pair with the
siRNA, resulting in escape from RNAi (240).
As previously mentioned, viruses can also escape destruction by experimentally
induced RNAi by developing mutations in the target region. These escape mutants have
been described in RNAi experiments with viruses including Polio (65), HIV (40), and
hepatitis C (247), appearing in cell culture after a few weeks. One single nucleotide
substitution in the central target region has been associated with interference escape (65,
104). Deletion (partial or complete) of the target region has been shown in HIV
experiments, as well as accumulation of several point mutations (40). It has been
suggested that in some cases, a single point mutation increases the level of resistance of
the virus, allowing further selective pressure to accumulate more point mutations, with
successive increases in the level of resistance (247). The difference observed in the level
of resistance conferred by point mutations is associated with the location of the mutation
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in the target sequence. Complete homology within the central region of the targeted
sequence is essential for silencing and substitutions at a few positions within the 3’ and 5’
ends of the target sequence are only partially tolerated (187). Nucleotides 2-8 in the
guide strand (antisense strand) are important for target recognition (seed region). The
first nucleotide does not contribute to target recognition; instead, it is sequestered in the
binding pocket of the endonuclease domain of the Argonaute protein. Nucleotides 9
through the 3’ terminal end have reduced importance for target recognition (70).
Targeting conserved sequences in essential viral genes is unlikely to result in
deletion of the target sequence as an escape mechanism. This would not likely be
maintained because it would not be consistent with life of the virus. Silent mutations are
more likely to occur, leading to changes in nucleotides but not amino acids (40).
Mutational associated escape is more likely to occur with RNA viruses, which lack
proofreading capability in the RNA polymerase (247). The viruses least likely to escape
RNAi are DNA viruses due to lower mutation frequencies (64). Development of escape
mutants has been shown to be prevented or decreased by using a combination of siRNAs
targeting different parts of the viral genome (247). Targeting multiple genes has been
shown to be more effective than targeting a single gene (169). However, with use of
multiple siRNAs, the RNAi machinery can become saturated, with no enhanced effect
(94) or result in degradation of untargeted genes (105).
Feline herpesvirus 1 is a suitable virus for targeting by RNAi. The virus, in the
vast majority of cases, produces a localized respiratory infection (37). Therefore, no
systemic administration of siRNAs is necessary, eliminating the challenge of targeted
delivery. In vivo studies have already demonstrated the effective uptake of siRNAs from
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mucosal surfaces (169), including effective intranasal delivery of siRNAs for treatment of
respiratory viruses (19, 114). FHV-1 is a DNA virus and due to lower mutation
frequencies of DNA viruses, escape mutation is not expected to be a significant problem
(64). Targeting conserved regions in essential genes is also less likely to lead to
mutational escape, and in targeting these genes, replication of the virus can be inhibited
(169). Targeting conserved regions also mitigates the problem of sequence diversity
between viral isolates (169). Fortunately, FHV-1 has an apparently low rate of genetic
variability between isolates (67). Previous studies have shown that targeting essential
genes in herpesviruses, including a herpesvirus DNA polymerase gene (241) and
glycoprotein B, an attachment protein gene (169), can effectively inhibit herpesvirus
replication. The glycoproteins that are essential for FHV-1 attachment and cell
penetration have not yet been determined, but the essential herpes simplex virus
glycoproteins are gD, gB, and gH-gL (162).
FHV-1 glycoprotein D and viral DNA polymerase genes were chosen as targets for
silencing for this study. FHV-1 glycoprotein D, an envelope protein, is the viral
hemagglutinin and an important contributor to viral infectivity. This glycoprotein is an
inducer of virus-neutralizing antibodies (125, 128). This gene also appears to be highly
conserved (243). FHV-1 glycoprotein D may play an important role in the restriction of
the host range of the virus to feline cells (131). In the related virus, herpes simplex virus
type 1, glycoprotein D is necessary for penetration of the virus into cells (116). It is an
essential receptor-binding polypeptide, binding to herpesvirus entry mediator A and
nectin-1 receptors on human cells (102). Therefore, like the DNA polymerase gene,
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FHV-1 glycoprotein D is expected to be essential for viral replication in feline cells. The
hypotheses for this study are as follows:
1. FHV DNA polymerase and gD genes are essential for FHV growth in vitro.
2. Silencing of either gene through mRNA destruction by RNA interference will
result in decreased viral infection in Crandell-Reese feline kidney cells.
3. Decreased viral infection will result in decreased viral titer, decreased viral
mRNAs, and decreased viral proteins.
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small interfering RNAs targeting the viral DNA polymerase
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Abstract
Feline herpesvirus 1 (FHV-1) is an alphaherpesvirus and produces the most
severe upper respiratory disease of cats. Symptoms include an ocular infection that
resembles the infection produced by the related virus, herpes simplex virus type 1, in
humans. Like all alphaherpesviruses, FHV-1 produces latent infections, and this virus is
widespread in the feline population. Vaccines are available but do not prevent infection
and antivirals are only minimally effective for treatment of chronic ocular infections in
cats. We evaluated RNA interference as a method to prevent FHV-1 infection in vitro.
Two siRNAs designed to target the viral DNA polymerase were effective in suppressing
viral replication. Therefore, RNA interference has potential as an antiviral therapeutic for
FHV-1 and this study lays the groundwork for potential in vivo investigations in cats.

Introduction
Feline herpesvirus 1 (FHV-1) is a member of the subfamily Alphaherpesvirinae
and consists of a single linear molecule of double-stranded DNA (31). FHV-1 is widespread in the feline population, with as many as 71% of cats seropositive for this virus
(20), and it causes 50% of the cases of upper respiratory disease in cats (23). Of these
infections, FHV-1 causes the most severe clinical disease (30). Acute infections are
usually localized to the respiratory tract, and clinical signs include pyrexia, ocular and
nasal discharge, rhinitis, tracheitis, and depression (7, 22). Primary ocular infection, as
occurs in humans with the related virus, herpes simplex virus type 1, consistently
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produces conjunctivitis and minimal corneal involvement. Acute signs, though
potentially severe, usually resolve in a few weeks (30).
FHV-1 is very fragile in nature and does not survive long outside the host, so
transmission requires close contact, especially mucosal contact, and sneezing and short
distance droplet spread are important in transmission in large confined populations, such
as in breeding colonies and rescue catteries (25). Upper respiratory infections in cats is
second only to overcrowding as the leading cause of euthanasia in shelters, and FHV-1 is
one of the most important causes of shelter respiratory disease (3).
FHV-1 has been perpetuated in nature as a result of its ability to produce latent
infections, and latently infected cats represent the most important reservoir of the virus
(11, 24). Approximately 80% of cats infected with the virus become latently infected
(11). During periods of stress such as changes in housing, parturition and lactation, or
with corticosteroid administration, recrudescence occurs with associated viral shedding,
with or without clinical disease. Also, 29% of latently infected cats are spontaneous
shedders.(11) Though the majority of latently infected cats do not develop chronic
clinical disease (1), there is still a large percentage of adult cats that have this problem
(34). The clinical manifestations of disease due to repeated recrudescence, including
corneal ulcerations (4), eosinophilic keratitis, or corneal sequestration (26), are
significant and can potentially lead to blindness (1).
Antiviral medications approved for treatment of herpes simplex virus type 1 in
humans are only minimally effective for treatment of these chronic cases in cats (35).
This is possibly due in part to the need for frequent application of the virostatic drugs to
be effective and poor owner compliance (35). Vaccines are available for FHV-1, but
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because the virus is poorly immunogenic (2), the vaccines do not prevent infection or
shedding and only produce partial protection from clinical disease (6). Therefore,
development of a new therapeutic for FHV-1 would be beneficial.
Recently, a mechanism called RNA interference (RNAi) has been manipulated for
prevention of various mammalian viral infections both in vitro and in vivo (18). RNA
interference is a double stranded RNA-guided gene silencing pathway that is found in a
variety of eukaryotic organisms, including yeast, plants, and mammals (for a review, see
reference (14). The double stranded RNA, small interfering RNAs (siRNA), that triggers
the pathway can be supplied exogenously to silence specific genes (10, 14).
The best method of suppressing viral infection is inhibiting viral replication (17).
Previous studies have shown that targeting essential genes in herpesviruses, including a
herpesvirus DNA polymerase gene (37), can effectively inhibit herpesvirus replication.
We have shown that siRNA designed to specifically target DNA polymerase gene
expression of FHV-1 can significantly reduce viral replication in vitro, and this gene is an
excellent target for antiviral therapy.

Materials and Methods
Cells and viruses: Crandell-Reese feline kidney (CRFK) cells (ATCC, Manassas,
VA) were propagated and maintained in Dulbecco’s minimal essential medium (DMEM)
(Cambrex, Charles City, IA) supplemented with heat-inactivated 5% fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA), 100 U/ml penicillin, 100µg/ml streptomycin,
and Fungizone (Cambrex) at 37˚C in a 5% CO2 incubator. The prototype FHV-1 strain
C-27 (ATCC) was used for the study. A calicivirus wild-type strain used in the study and
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10 FHV-1 isolates from 2003-2006 were a generous gift from the Clinical Virology
Laboratory, University of Tennessee, Knoxville, TN.
siRNAs and transfection: Five siRNAs designed to target the DNA polymerase
mRNA of FHV-1 were produced by Ambion- Applied Biosystems (Austin, TX) (Table
2.1). The FHV-1 sequences targeted by the siRNAs are identical in each of the FHV-1
DNA polymerase sequences contained in GenBank and in an additional 10 isolates
obtained from cats from 2003-2006. Transfections of 100 nM siRNA per well in six well
plates were performed with 5 µL of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) per
sample using Opti-MEM (Gibco-Invitrogen), according to manufacturer’s protocol.
Approximately 5 x 104 CRFK cells diluted in DMEM supplemented with 10% FBS were
added to each well containing the transfection mixtures. Plates were incubated for 24
hours prior to infection with FHV-1. Each siRNA was tested in duplicate, and functional
siRNAs were retested for a total of three experiments per siRNA. A non-targeting
negative control siRNA was purchased from Ambion. siRNAs targeting the feline
GAPDH gene, also obtained from Ambion, were used as a positive control to verify
effective siRNA transfection (Table 2.1). Other controls used for each experiment
included uninfected/mock-transfected CRFK cells, FHV-1 infected/non-transfected cells,
and a type 1 interferon control. The type 1 interferon control consisted of non-transfected
CRFK cells infected with feline calicivirus, an RNA virus that activates interferon β in
CRFK cells.
Virus infection and plaque assays: The FHV-1 strain C-27 (ATCC) was grown
in CRFK cells until 50% cytopathic effect was visible. Plaque forming units were
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TABLE 2.1 siRNA designed to target mRNA.
siRNA

Antisense sequence (5’→3’)

Feline GAPDH
GAP 1
GAP 2
GAP 3

Based on GenBank accession AB038241
UGCUUCACCACCUUCUUGAtga
UGAGCUUCCCAUUCAGCUCtg
AGAAGCAGGGAUGAUGUUCtg

FHV DNA
Polymerase
DNA 1
DNA 2
DNA 3
DNA 4
DNA 5

Based on GenBank accession AF079125 (15)
UGAGUAGCAUAUCUCUUCCta
GGUCAUAGCUUCUGGAAAAtc
UUUCGACUCCUUCUCUAGUtg
CUAGACUCCACGUAAUGUUta
AGACAUGGGAGAAGACCAUta

Location
targeted
785-767
679-661
624-606

70-52
144-126
121-103
95-77
23-5

a. Upper case letters represent guide sequence, lower case letters represent 3’ overhangs
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determined by plaque assay as previously described (8). However, instead of using an
agarose overlay, serum from a cat with an IFA titer of >1:2560 (a gift from the University
of Tennessee Clinical Virology Lab) was used at a dilution of 1:50. Aliquots of virus
were prepared and frozen at -80ºC, and each aliquot was used only once for each
experiment.
Transfected CRFK cells were infected with FHV-1 at a MOI of 0.1. One hour
after incubation, the cells were washed with DMEM and fresh DMEM supplemented
with 10% FBS was added to each well. Infected cells were incubated for a total of 48
hours. 500 µL of cell culture medium was removed from each well at 48 hours and
stored at -80˚C until plaque assays could be performed.
Flow Cytometry: Forty-eight hours after infection, the cells in each test and
control well were trypsinized, washed with phosphate-buffered saline (PBS) (GibcoInvitrogen), and resuspended in 1 mL of PBS per sample. 100µL of each suspension was
removed and placed on ice for later RNA extraction. An additional 100 µL of each
suspension was removed and processed for Western blot analysis, and the rest of each
sample was processed for flow cytometry.
The flow cytometry samples were washed in flow buffer (60 mL 0.5% sodium
azide solution, 87 mL PBS, and 3 mL FBS) and the cells were pelleted. The cells from
each sample were stained with 200 µL fluorescein isothiocyanate-labeled cat anti-FHV
polyclonal antibody (Accurate Chemical and Scientific Corp., Westbury, NY) for one
hour on ice. The cells were washed in PBS and were resuspended in 1mL PBS per
sample. Cell surface fluorescence was assessed with an Epics XL flow cytometer
(Beckman Coulter, Fullerton, CA).
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Western blot analysis: Cells were combined with SDS sample buffer and boiled
for five minutes. Samples were stored at -20ºC until later assayed. Proteins were
electrophoresed on 10% polyacrylamide gels and transferred to nitrocellulose membranes
(Bio- Rad, Hercules, CA). The membranes were probed with CRFK adsorbed cat antiFHV-1 polyclonal antibody (Accurate Chemical and Scientific Corp.) or an anti-GAPDH
monoclonal antibody (Chemicon International- Millipore, Billerica, MA), and an anti-β
actin monoclonal antibody (Ambion) was used as a loading control. Samples were
incubated for 1 hour on a shaker at room temperature. The membranes were washed five
times and probed with peroxidase labeled goat anti-mouse IgG (GAPDH and beta actin
monoclonals) or peroxidase labeled goat anti-feline IgG (FHV polyclonal) secondary
antibodies (KPL, Gaithersburg, Maryland) for one hour on a shaker at room temperature.
Five additional washes were performed, and proteins were detected by enhanced
chemiluminescnece (Amersham Biosciences, Piscataway, NJ). The density of the protein
bands was determined with a visible scanning densitometer (Quick Scan 2000, Helena
Laboratories, Beaumont, TX).
RNA extraction and real-time RT-PCR: Total RNA was extracted from 100 µL
aliquots of each test and control sample with the RNeasy Mini Kit (Qiagen, Valencia,
CA) according to manufacturer’s protocol. Two on-column DNase digestions (Qiagen)
were performed for each RNA sample, and the samples were diluted 1:1000 to reduce
DNA contamination. Purified RNA samples were stored at -80˚C until tested by realtime RT-PCR. Primers and probes for real-time RT-PCR were designed with Primer3
(32) to detect FHV-1 DNA polymerase and interferon β mRNA (Table 2.2). 28S rRNA
was used as a control to standardize RNA concentration (Table 2.2). Primers, probe, and
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TABLE 2.2 Primers and probes used to detect mRNA.
Primer/Probe
FHV DNA
polymerase
Forward
Reverse
Probe

Sequence (5’→3’)
Based on GenBank accession AJ224971 (38)

Location

CGGAGGGAAAATGCTTATGA
ATCCATTCTCTGGGATGCAC
TCAATACATACGCTCGCCGATTAGTGGATA

3328-3347
3486-3467
3387-3416

Interferon beta
Forward
Reverse
Probe

Based on GenBank accession AB021707
ATTGCCTCAAGGACAGGATG
CAGGATCGTTTCCAGGTGTT
TTTTCAGTAGAAGCACCTCTAGCACGGGAT

237-256
454-435
354-383

28S rRNA
Forward (16)
Reverse (16)
Probea

Based on GenBank accession AF353617 (16)
CGCTAATAGGGAATGTGAGCTAGG
TGTCTGAACCTCCAGTTTCTCTGG
AGACCGTCGTGAGACAGGTTAGTTTTACCC

663-686
783-760
690-719

GAPDH (28)
Forward
Reverse
Probe

Based on GenBank accession AB038241
GCTGCCCAGAACATCATCC
GTCAGATCCACGACGGACAC
TCACTGGCATGGCCTTCCGT

598-616
731-712
677-696

a. Probe designed from sequence obtained from real-time RT-PCR product from
CRFK cells
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RT-PCR cycling parameters for feline GAPDH were previously published (28) (Table
2.2). RT-PCR was performed for each transcript using the SuperScript III Platinum OneStep qRT-PCR kit (Invitrogen). 5 µL of diluted RNA was used in 25 µL total volume
reactions, which contained 200nM of each probe and 300nM of each primer, and 40U of
RNaseOut recombinant ribonuclease inhibitor (Invitrogen). Amplification of FHV-1
DNA polymerase was carried out in a SmartCycler® II (Cepheid, Sunnyvale, CA) with
the following parameters: cDNA production at 45ºC for 30 min, hot start Taq polymerase
activation at 95ºC for 2 minutes, followed by 45 cycles of denaturation at 95ºC for 15
seconds, annealing at 55ºC for 60 seconds, and extension at 72ºC for 30 seconds. The
parameters for interferon β and 28S rRNA were as follows: cDNA production at 42ºC
(interferon) or 50ºC (28S) for 30 minutes, 95ºC for two minutes, followed by 45 cycles of
95ºC for 15 seconds, 60ºC (interferon) or 62ºC (28S) for sixty seconds, and 72ºC for 30
seconds. Extensive DNA contamination was ruled out by RTase negative controls, which
were run with Platinum taq (Invitrogen) instead of SuperScript III. Each set of samples
was run with three mRNA standard dilutions, generating curves for mRNA quantitation.

mRNA standards and standard curve production:

mRNA standards were

produced for FHV-1 DNA polymerase and feline GAPDH by ligating each PCR product
into a pCR2.1 plasmid vector, and the recombinants were transduced into Escherichia
coli (TA Cloning Kit, Invitrogen). The plasmids were isolated (SNAP MiniPrep Kit,
Invitrogen), and the identity and orientation of the cloned products were determined by
sequencing (Molecular Biology Resources Service, University of Tennessee, Knoxville,
TN). The plasmids were linearized (Hind III, Fisher Scientific), and used for in vitro
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transcription (AmpliCap T7 High Yield Message Maker Kit-Epicentre Biotechnologies,
Madison, WI). Following treatment with DNase (Qiagen), the mRNA transcripts were
purified (RNeasy Mini Kit, Qiagen). These standards were used to produce standard
curves for absolute quantitation of FHV-1 DNA polymerase and feline GAPDH mRNA
transcripts isolated from the samples. The RNA concentration and purity of the standards
were determined by spectrophotometrical analysis at OD 260/280 (BioPhotometer 6131
spectrophotometer, Eppendorf, Westbury, NY).

The number of RNA copies in the

sample was estimated based on the molecular weight of the RNA standards and the RNA
concentration. Ten fold serial dilutions of the RNA stock were prepared, and aliquots
were made and frozen immediately at −80°C. Each aliquot was used only once for realtime RT-PCR.
A standard curve was generated by testing 10-fold serial dilutions of the standard
RNA by real-time RT-PCR and the standard curve was generated by the SmartCycler® II
software (Cepheid). The intra-assay and inter-assay coefficients of variation of the
reactions were determined using dilutions of the standard RNA as previously described
(33). To ensure the standard RNA and the target RNA were amplified with similar
efficiencies according to the calculation: Efficiency = [10(-1/slope)] -1 (40), four 10-fold
serial dilutions of RNA extracted from a CRFK control well and an FHV infected control
well were also prepared and tested in quadruplicate by real-time RT-PCR.
Statistical analysis: The results for the DNA polymerase specific siRNA test and
control groups were compared by using univariate ANOVA (SPSS software) because all
assumptions were met, based on the Levene’s test for equality of variances and the
Shapiro-Wilk test for normality. The real-time RT-PCR results for GAPDH specific
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siRNA control groups were compared using the Mann-Whitney Test because the results
lacked a normal distribution. Univariate ANOVA and a Post Hoc Dunnett T3 test were
used to compare controls with GAPDH specific siRNA treatment groups because there
were unequal variances between treatment groups.

Results
RNAi of feline GAPDH: In order to determine if RNAi could be performed in
CRFK cells with siRNAs transfected with Lipofectamine 2000, an endogenous gene,
feline GAPDH, was chosen as a target. CRFK cells were transfected with each GAPDH
specific siRNA separately and compared to negative control siRNA transfected cells and
mock-transfected cells. Forty-eight hours following transfection, knockdown of GAPDH
mRNA was assessed by quantitative real-time RT-PCR. RNA was standardized by 28S
rRNA, which had a reaction efficiency of 102% (data not shown). GAPDH mRNA copy
numbers were calculated from the standard curve, which was linear over five orders of
magnitude (slope = -3.299) and resulted in a theoretical limit of detection of 24 copies
(Figure 2.1). The intra-assay variation within the portion of the curve used for mRNA
copy calculations was 10-35% based on copy numbers (0.58-1.95% based on Ct values),
and the inter-assay variation was 18-43% based on copy numbers (1.15-2.26% based on
Ct values). The GAPDH specific siRNA, GAP1, GAP2, and GAP3, resulted in
decreased GAPDH mRNA by 86%, 83%, and 93%, respectively, compared to the
control, which consisted of an average of the results from the negative control siRNA
transfected and mock-transfected CRFK cells (Figure 2.2). The knockdown of GAPDH
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FIGURE 2.1 GAPDH standard curve. The GAPDH standard curve was generated by
testing five 10-fold serial dilutions of GAPDH standard RNA, and the theoretical limit of
detection was 24 copies. The efficiency of the reaction was 101%, compared to the
efficiency of 10-fold serial dilutions of GAPDH mRNA of 102% (not shown).

76

Copies of GAPDH mRNA/5uL
RNA

350000
300000
250000
200000
150000
100000
50000
0
Control GAP1

GAP2

GAP3

FIGURE 2.2 Knockdown of feline GAPDH mRNA by siRNAs. CRFK cells were
transfected with feline GAPDH specific siRNAs (GAP1, GAP2, GAP3) or negative
control siRNA. Following 48 hours incubation, total RNA was extracted from cells and
tested by real-time RT-PCR with primers specific for GAPDH mRNA or 28S rRNA.
The samples were normalized with 28S rRNA and copies of GAPDH mRNA were
estimated from a standard curve generated by 10-fold serial dilutions of a GAPDH RNA
standard. Three independent experiments were performed and the results show the
means of the experiments; error bars represent 1 standard deviation from the means.
GAP1 is statistically different than the control (P= 0.026), GAP2 is statistically different
than the control (P= 0.029), and GAP3 is statistically different than the control (P= 0.019)
based on statistical analysis. Control = average of results from mock-transfected and
negative control siRNA transfected CRFK cells (not statistically different, P= 1).
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mRNA was independent of type 1 interferon production, determined by insignificant
interferon β mRNA production in siRNA treated cells (similar to the amount detected in
mock-transfected cells) compared to the control, CRFK cells infected with feline
calicivirus, an interferon β activator (data not shown).
GAPDH mRNA knockdown also resulted in reduced GAPDH protein expression.
GAPDH protein was reduced by 43%, 24%, and 64%, by GAP1, GAP2, and GAP3,
respectively, compared to non-treated and negative siRNA treated controls (Figure 2.3).
Knockdown of DNA polymerase mRNA by RNAi: Following the successful
knockdown of GAPDH in CRFK cells by RNAi, we next evaluated RNAi directed
against the DNA polymerase gene of FHV-1 in CRFK cells. CRFK cells were
transfected separately with each of the five siRNAs designed to target the FHV-1 DNA
polymerase mRNA or with negative control siRNA in six well plates 24 hours prior to
infection with FHV-1, and these samples were compared to a non-transfected, FHV-1
infected control. Forty-eight hours following infection, total RNA was extracted and
tested for FHV-1 DNA polymerase mRNA by quantitative real-time RT-PCR. The RNA
in each sample was normalized with 28S rRNA. Copies of mRNA were calculated from
the standard curve, which was linear (slope = -3.406), spanning six orders of magnitude,
and resulted in a theoretical detection limit of 15 copies (Figure 2.4). The results were
reproducible, with intra-assays of variation of 6-15% based on copy numbers (0.330.91% based on Ct values) and inter-assays of variation of 14-21% based on copy
numbers (0.73-1.44% based on Ct values) within the portion of the curve used to
calculate DNA polymerase mRNA copies. Two of the five siRNAs tested produced
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FIGURE 2.3 Reduction of GAPDH protein expression by siRNAs. CRFK cells were
transfected with 100 nM each of feline GAPDH specific siRNAs (GAP1-3) and total
cellular material was harvested after 48 hours incubation. Western blot analysis was
performed with anti-GAPDH and anti-beta actin monoclonal antibodies. Each siRNA
was run in duplicate (a,b) with a CRFK control transfected with negative control siRNA
(N) and a CRFK mock-transfected control (C). Beta-actin was used as a loading control
to normalize protein concentrations, and the density of the protein bands was determined
with a visible scanning densitometer. The results of a representative experiment are
shown.
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FIGURE 2.4 DNA polymerase standard curve. The FHV-1 DNA polymerase standard
curve was generated by testing six 10-fold serial dilutions of DNA polymerase standard
RNA, and the theoretical limit of detection is 15 copies. The efficiency of the reaction
was 97-100%, compared to the efficiency of 10-fold serial dilutions of DNA polymerase
mRNA of 105% (not shown). Therefore, this standard curve was suitable for estimation
of copy numbers of DNA polymerase mRNA.
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significant reduction in DNA polymerase mRNA compared to the control, resulting in
83% reduction by DNA1 and 69% reduction by DNA3 (Figure 2.5). RNAi knockdown
of the DNA polymerase mRNA was independent of type 1 interferon production (Figure
2.6).
Reduction in FHV-1 protein expression by RNAi: Knockdown of FHV-1 DNA
polymerase by DNA1 and DNA3 also resulted in decreased expression of FHV-1
proteins in treated cells compared to negative siRNA control treated cells and untreated,
FHV-1 infected cells. Total protein was isolated from the infected cells and tested by
Western blot (Figure 2.7); cells were also tested by flow cytometry to determine the
amount of FHV-1 proteins on the surface of FHV-1 infected, DNA polymerase specific
siRNA treated cells versus FHV-1 infected, negative siRNA control treated cells (Figure
2.8). DNA1 reduced cell surface FHV-1 glycoproteins on infected cells by 71% and
DNA3 reduced cells surface FHV-1 glycoproteins by 29%, compared to the negative
control siRNA treated cells.
FHV-1 DNA polymerase specific siRNAs inhibit FHV-1 replication in vitro: As
expected and suggested by the decreased viral protein expression in DNA1 and DNA3
treated cells, RNAi directed against FHV-1 DNA polymerase mRNA inhibited
replication of the virus in CRFKs. Infectious FHV-1 was detected in the cell culture
supernatants of siRNA treated cells and controls by plaque assay. DNA1 siRNA
inhibited FHV-1 replication by 96%, and DNA3 by 83%, compared to the control (Figure
2.9). Inhibition of replication was also evident by the indirect knockdown of the
untargeted viral mRNA coding for glycoprotein D (Figure 2.10).
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FIGURE 2.5 Knockdown of FHV-1 DNA polymerase mRNA by siRNAs. CRFK
cells were transfected with FHV-1 DNA polymerase specific siRNAs (DNA1 and
DNA3) or negative control siRNA 24 hours prior to infection with FHV-1 (MOI= 0.1).
Following 48 hours incubation, total RNA was extracted from cells and tested by realtime RT-PCR with primers specific for DNA polymerase or 28S rRNA. The samples
were normalized with 28S rRNA and copies of DNA polymerase mRNA were estimated
from a DNA polymerase standard curve generated by 10-fold serial dilutions of a DNA
polymerase RNA standard. Three independent experiments were performed and the
results show the means of the experiments; error bars represent 1 standard deviation from
the means. DNA1 is statistically different than the control (P= 0.006) and DNA3 is
statistically different than the control (P= 0.015) based on univariate ANOVA analysis.
Control = average of the results from non-treated and negative control siRNA treated
FHV-1 infected cells (not statistically different, P = 0.33)
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a

b

FIGURE 2.6 Interferon β real-time RT-PCR. Knockdown of FHV-1 DNA
polymerase mRNA is siRNA specific and not the result of type 1 interferon induction.
Interferon β mRNA copy numbers in samples treated with DNA1/DNA3 (b) are similar
to the copy numbers detected in the untreated samples (b) and are much lower than the
copy numbers detected in cells infected with calicivirus (a), an interferon β inducer.
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FIGURE 2.7 FHV-1 DNA polymerase specific siRNAs knockdown FHV-1 protein
expression. Negative control siRNA (C) or FHV-1 DNA polymerase specific siRNAs
(DNA1/DNA3) were transfected into CRFK cells 24 hours prior to infection with FHV-1
(MOI = 0.1). 48 hours following FHV-1 infection, total cellular material was
electrophoresed on 10% SDS polyacrylamide gels. Proteins were transferred to
nitrocellulose membranes, and membranes were probed with anti-FHV-1 polyclonal
antibodies or an anti-GAPDH monoclonal antibody, as indicated.
1- Negative control siRNA treated, FHV-1 infected cells (N); 2-non-treated, non-infected
cells (C); 3 & 4- duplicates of DNA1 treated, FHV-1 infected cells; 5 & 6- duplicates of
DNA3 treated, FHV-1 infected cells
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a)

b)

FIGURE 2.8 FHV-1 DNA polymerase specific siRNAs decrease expression of FHV1 proteins on the surface of infected CRFK cells. Cells were transfected with negative
control siRNA, or FHV-1 DNA polymerase specific siRNA, DNA1 (a) or DNA3 (b), 24
hours prior to FHV-1 infection (MOI = 0.1). 48 hours following infection, cells were
incubated with anti-FHV-1 polyclonal antibodies. Fluorescence intensity increases from
left to right, and 104 cells/sample were analyzed. The data are representative of three
independent experiments. Color key: black- uninfected CRFKs, gray- FHV-1 infected,
DNA polymerase specific siRNA treated CRFKs, white- FHV-1 infected, negative
control siRNA treated CRFKs
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FIGURE 2.9 FHV-1 DNA polymerase specific siRNAs inhibit FHV-1 replication in
CRFK cells. Cells were transfected with negative control siRNA, or DNA polymerase
specific siRNA (DNA1/DNA3), 24 hours prior to FHV-1 infection (MOI= 0.1). 48 hours
following infection, cell culture supernatant was collected and tested in duplicate by
plaque assay. The experiment was repeated three times, and the results are shown as
averages from the three experiments, with error bars representing 1 standard deviation
from the means. The titers from the DNA1 and DNA3 treated samples are statistically
different from the titers for the untreated and negative siRNA treated control samples
(Control), with P values of <0.001 (univariate ANOVA).
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FIGURE 2.10 Decreased FHV-1 glycoprotein D mRNA by DNA polymerase
specific siRNA treatment. CRFK cells were transfected with FHV-1 DNA polymerase
specific siRNAs (DNA1 or DNA3) or negative control siRNA (C) 24 hours prior to
infection with FHV-1 (MOI= 0.1). Following 48 hours incubation, total RNA was
extracted from cells and tested by real-time RT-PCR with primers specific for FHV-1
glycoprotein D mRNA (see Part 3). These results are from a single representative
experiment.
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Discussion
We used RNAi to target the DNA polymerase gene of feline herpesvirus 1 and
demonstrated significant suppression of viral replication by knockdown of the DNA
polymerase mRNA. Based on the results of this study, the FHV-1 DNA polymerase gene
is an excellent target for RNAi anti-viral treatment.
FHV-1 is a suitable virus for targeting by RNAi. The virus, in the vast majority
of cases, produces a localized respiratory infection (9). Therefore, no systemic
administration of siRNAs is necessary, eliminating the challenge of targeted delivery. In
vivo studies have already demonstrated the effective uptake of siRNAs from mucosal
surfaces (29), including effective intranasal delivery of siRNAs for treatment of
respiratory viruses (5, 21). RNAi has also been shown to be effective in treatment of
ocular disease (18).
A potential benefit of using RNAi therapy for treatment of chronic FHV-1 ocular
infections is the relatively long-term silencing obtained with RNAi. In this study, we
showed knockdown that lasted at least 72 hours after a single transfection. Therefore,
unlike the current herpesvirus antiviral treatments which must be applied 4-6 times per
day to be effective (35), siRNAs could be used much less frequently.
Silencing can be enhanced by consecutive applications of siRNAs into virus
infected cells; however, this can lead to selection of mutants that have changes in the
target region (39), especially in chronic infections with RNA viruses that produce
quasispecies populations (19). FHV-1 is a DNA virus and due to lower mutation
frequencies of DNA viruses, escape mutation is not expected to be a significant problem
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(12). Targeting conserved regions in essential genes is also less likely to lead to
mutational escape, and in targeting these genes, replication of the virus can be inhibited
(29).
Targeting conserved regions also mitigates the problem of sequence diversity
between viral isolates (29). Fortunately, FHV-1 has an apparently low rate of genetic
variability between isolates (13). The region of the DNA polymerase gene targeted in
this study codes for highly conserved amino acid motifs of herpesvirus DNA polymerase
genes, is unique to each viral species, and lacks DNA sequence drift for
alphaherpesviruses, including herpes simplex virus type 2 (36) and feline herpesvirus, as
determined in this study.
Development of escape mutants has been shown to be prevented or decreased by
using a combination siRNAs targeting different parts of the viral genome (39). Also,
targeting multiple genes has been shown to be more effective than targeting a single gene
(29). Therefore, a better method of FHV-1 RNAi would also incorporate siRNAs that
target another essential gene. One candidate is FHV-1 glycoprotein D (see Part 3).
This study lays the groundwork for potential in vivo investigations in cats, the
natural host of this virus, and a model that more closely resembles the HSV-1 infection in
humans, compared to rabbit or mouse HSV-1 models (27). Such studies may provide
unique insights into the prevention/treatment of herpesvirus infections by RNAi.
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Part 3 Feline herpesvirus 1 glycoprotein D is essential for in
vitro replication and is a potential target for antiviral therapy
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Abstract
RNA interference (RNAi), a gene regulatory mechanism conserved in eukaryotes,
has been successfully reprogrammed in mammalian cells to inhibit expression of viral
genes, functioning in anti-viral defense, similar to its natural biological role in plants.
Inhibiting viral genes in infected cells has allowed determination of the role of those
genes in infection. In this study, we used RNAi to examine the function of feline
herpesvirus 1 (FHV-1) glycoprotein D in the infection of feline cells. We determined
that glycoprotein D is necessary for production of infective virions, suggesting FHV-1
glycoprotein D is necessary for viral attachment and/or penetration of host cells, similar
to its counterpart in the related virus, herpes simplex type 1. Two chemically produced
siRNAs targeting the glycoprotein D gene significantly reduced virus titers in treated
cells; therefore, this gene is a potential target for RNAi anti-viral therapy.

Introduction
RNA interference (RNAi) is a RNA-guided gene regulatory mechanism that is
found in a variety of eukaryotic organisms, including yeast, plants, and mammals. This
cellular machinery is known to be activated by double-stranded RNA (9), which is
chopped into duplexes of approximately 21 nucleotides called small interfering RNAs
(siRNAs) (8) by a member of the RNase III family of ATP-dependent ribonucleases
called Dicer (3). The siRNA duplexes are incorporated into the RNA induced silencing
complex (RISC). RISC then targets homologous transcripts by base pairing and cleaves
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the mRNA (11). The mRNA is further degraded by exonucleases (for a review, see
reference 10).
siRNAs can be produced and delivered to cells to silence specific genes of
interest, and chemically produced siRNAs of 21 nucleotides have been used routinely for
RNAi experiments since the time they were discovered to initiate RNAi in mammalian
cells (7). RNAi can also be activated in mammalian cells by longer siRNAs, 27-mers,
which were shown to be more potent inducers of RNAi than 21-mers. These longer
siRNAs are processed by Dicer and therefore, the resultant siRNAs are more efficiently
incorporated into RISC (17).
RNA interference, initiated by exogenous siRNAs, has been used successfully in
previous experiments to determine the function of viral genes (26, 27), and also used
therapeutically for mammalian viral infections (reviewed in (16). One method of
suppressing viral replication in cells is by silencing viral attachment proteins (1) (30).
Feline herpesvirus 1 (FHV-1) glycoprotein D, an envelope protein, is the viral
hemagglutinin and an inducer of virus-neutralizing antibodies (22, 23). This gene also
appears to be highly conserved (36). FHV-1 glycoprotein D may play an important role
in the restriction of the host range of the virus to feline cells (24). It is unknown if FHV1 glycoprotein D is a viral attachment protein, but in the related virus, herpes simplex
virus type 1, glycoprotein D is an attachment protein and is essential for entry of the virus
into cells (20, 21, 29).
We hypothesized that FHV-1 glycoprotein D, like its homolog in herpes simplex
virus type 1, is necessary for viral infection. We used both 21-mer and 27-mer siRNAs to
knockdown the expression of this gene and have shown that it is likely involved with
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viral attachment and/or penetration and is an appropriate target for RNAi anti-viral
treatment.

Materials and Methods
Cells and viruses: Crandell-Reese feline kidney (CRFK) cells (ATCC, Manassas,
VA) were propagated and maintained in Dulbecco’s minimal essential medium (DMEM)
(Cambrex, Charles City, IA) supplemented with 5% heat-inactivated fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA) and standard concentrations of penicillin,
streptomycin and Fungizone (Cambrex) at 37˚C in a 5% CO2 incubator. The FHV-1
strain used was the prototype strain C-27 (ATCC). A calicivirus wild-type strain used in
the study was a generous gift from the Clinical Virology Laboratory, University of
Tennessee College of Veterinary Medicine.
siRNAs and transfection: Both 21-mer (Ambion- Applied Biosystems, Austin,
TX) and 27-mer (IDT, Coralville, IA) siRNAs were used to target the glycoprotein D
gene of FHV-1 (Table 3.1). The 21-mers were designed by Ambion, and the 27-mers
were designed with the IDT siRNA design tool. These sequences were compared with
known sequences in the GenBank database to decrease off-target effects by avoiding
similar sequences in the feline genome. The portion of the FHV-1 glycoprotein D coding
sequence targeted by the siRNAs is identical in each of the isolates in the GenBank
database, in the prototype strain used in the study, and in an additional 10 isolates (20032006) obtained from the Clinical Virology Laboratory, University of Tennessee College
of Veterinary Medicine. Negative control 21-mer and 27-mer siRNAs were purchased
from Ambion and IDT, respectively. A Cy-5 labeled control siRNA (IDT) was used as a
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TABLE 3.1 siRNA designed to target FHV-1 glycoprotein D mRNA.
siRNA

Antisense sequence (5’→3’)

Location
targeted

FHV glycoprotein D
gD 1
gD 2
gD 3

Based on GenBank accession D30767 (23)
UGGUUAUAACUCUUCGAUAUUGUCCuua
CAUCAUAAUCAAACCCAGUUCAUCGuc
UUGAUGUUACAUAACGUACUUCAGCug

1397-1379
1351-1333
1076-1058

G1
G2
G3

AAUCAAACCCAGUUCAUCGtcb
AAUAGUGGUAAUCACGAGCtc
UUUAUGGUGAGGUUGUGGGtt

1351-1333
1556-1538
1591-1573

a. Bold letters represent guide sequence subsequent to processing by Dicer, lower
case letters represent 3’ overhangs
b. Upper case letters represent guide sequence, lower case letters represent 3’
overhangs
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transfection control. Transfections were performed with Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) in Opti-MEM (Gibco-Invitrogen), according to manufacturer’s protocol.
Five µL of Lipofectamine 2000 was used to transfect 100 nM 21-mer siRNAs per well
and 50 nM 27-mer siRNAs per well in six well plates. Approximately 5 x 104 CRFK
cells diluted in DMEM, supplemented with 10% FBS, were added to each well
containing the transfection mixtures. Plates were incubated for 24 hours prior to
infection with FHV-1. Each siRNA was tested in duplicate, and functional siRNAs were
retested for a total of three experiments per siRNA. Additional controls used for each
experiment included uninfected/non-transfected CRFK cells, infected/non-transfected
cells, and an interferon β control, which consisted of non-transfected CRFK cells infected
with feline calicivirus, an RNA virus that activates interferon β in CRFK cells.
Plaque assays: FHV-1 strain C-27 was grown in CRFK cells until 50%
cytopathic effect was produced. The titer of the virus was determined by plaque assay as
previously described (5), with the exception of using an agarose overlay. Instead, serum
from a cat with an IFA titer of >1:2560 (a gift from the University of Tennessee Clinical
Virology Lab) was used at a dilution of 1:50.
Transfected CRFK cells were infected with FHV-1 at a MOI of 0.1. One hour
after incubation, the cells were washed with DMEM and fresh DMEM supplemented
with 10% FBS was added to each well. Infected cells were incubated for a total of 48
hours. 500 µL of cell culture medium was removed from each well after 48 hours and
stored at -80˚C for plaque assay. Infective virus titers (PFU) were determined for each
well by plaque assay.
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Flow cytometry: Prior to infection with FHV-1, (24 hours after transfection) the
transfection control well was tested to determine transfection efficiency. The cells were
trypsinized and washed in phosphate buffered saline (PBS) (Gibco- Invitrogen) and flow
buffer (60 mL 0.5% sodium azide solution, 87 mL PBS, and 3 mL FBS), and
resuspended in 1 mL PBS. Transfection efficiency was determined by analyzing
intracellular Cy-5 fluorescence with a Beckman Coulter Epics XL flow cytometer
(Fullerton, CA). Following FHV-1 infection and 48 hours incubation, the cells in each
test and control well were trypsinized, washed with PBS, and resuspended in 1 mL of
PBS per sample. 100µL of each suspension was removed and placed on ice for RNA
extraction, and the rest of each sample was processed for flow cytometry. The flow
cytometry samples were washed in flow buffer, divided in half, and the cells were
pelleted. Half of each sample was stained with 200 µL fluorescein isothiocyanate-labeled
anti-FHV-1 polyclonal antibody (Accurate Chemical and Scientific Corp., Westbury,
NY) and the remainder was stained with the primary monoclonal antibody FHV 7-5, a
generous gift from Dr. Chris Grant (Custom Monoclonals International, Sacramento, CA)
at a dilution of 1:50 in PBS for 1 hour on ice. The cells were then washed and the cells
previously treated with the primary antibody were treated with 2 µL of the secondary
antibody, fluorescein isothiocyanate-labeled F(ab’)2 rabbit anti-mouse immunoglobulin
G (Southern Biotech, Birmingham, AL) for one hour on ice. The cells treated with the
polyclonal antibody were resuspended in 1 mL PBS per sample and stored at 4˚C until
analyzed. After a final wash for the remaining cells, they were resuspended in 1mL PBS
per sample, and all the samples were analyzed by flow cytometry.
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RNA extraction and real-time RT-PCR: Total RNA was extracted from 100 µL
aliquots of each test and control sample with the RNeasy Mini Kit (Qiagen, Valencia,
CA) according to manufacturer’s protocol. The RNA samples were treated with two oncolumn DNase digestions (Qiagen) and diluted 1:1000 to reduce DNA contamination.
Purified RNA samples were stored at -80˚C until tested by real-time RT-PCR. Primers
and probes for real-time RT-PCR were developed with Primer3 (32) to detect FHV-1
glycoprotein D and interferon β mRNA (Table 3.2). 28S rRNA was used as a control to
standardize RNA concentration (Table 3.2). Real-time RT-PCR was performed for each
transcript using the SuperScript III Platinum One-Step qRT-PCR kit (Invitrogen) in a
SmartCycler® II (Cepheid, Sunnyvale, CA). Five µL of diluted RNA was used in 25 µL
total volume reactions, which contained 200 nM of each probe and 300 nM of each
primer. The reaction conditions for glycoprotein D and interferon β were
reverse transcription at 42ºC for 30 minutes, an initial heat step of 95ºC for two minutes
to activate the hot start Taq polymerase, followed by 45 cycles of 95ºC for 15 seconds,
50ºC (glycoprotein D) or 60ºC (interferon β) for 60 seconds, and 72ºC for 30 seconds.
The reaction conditions for 28S rRNA were reverse transcription at 50ºC for 30 minutes,
95ºC for two minutes, and 45 cycles of 95ºC for 15 seconds, 62ºC for 60 seconds, and
72ºC for 30 seconds. RTase negative controls were run using Platinum Taq (Invitrogen),
replacing SuperScript III, to rule out excessive DNA contamination. Each set of samples
was run with mRNA standard dilutions to validate mRNA quantitation.
mRNA standards and standard curve production: mRNA standards were
produced for glycoprotein D and interferon β by cloning the PCR products into plasmid
vectors and transducing Escherichia coli (TA Cloning Kit, Invitrogen). Recombinant
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TABLE 3.2 Primers and probes used to detect mRNA.
Primer/Probe
Glycoprotein D
Forward
Reverse
Probe

Sequence (5’→3’)
Based on GenBank accession D30767 (23)
CCTTGATGGAGCTCGTGATT
TCGAATCCTCACTCCCAGAC
ACCCTATAACCCACAACCTCACCATAAAGC

Location
1528-1547
1564-1573
1700-1681

Interferon β
Forward
Reverse
Probe

Based on GenBank accession AB021707
ATTGCCTCAAGGACAGGATG
CAGGATCGTTTCCAGGTGTT
TTTTCAGTAGAAGCACCTCTAGCACGGGAT

237-256
454-435
354-383

28S rRNA
Forward (12)
Reverse (12)
Probea

Based on GenBank accession AF353617 (12)
CGCTAATAGGGAATGTGAGCTAGG
TGTCTGAACCTCCAGTTTCTCTGG
AGACCGTCGTGAGACAGGTTAGTTTTACCC

663-686
783-760
690-719

a. Probe designed from sequence obtained from real-time RT-PCR product from
CRFK cells
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plasmids were isolated (SNAP MiniPrep Kit, Invitrogen), sequenced (Molecular Biology
Resources Service, University of Tennessee, Knoxville, TN), linearized (Hind III, Fisher
Scientific), and used for in vitro transcription (AmpliCap T7 High Yield Message Maker
Kit-Epicentre Biotechnologies, Madison, WI). mRNA transcripts were treated with
DNase (Qiagen) and purified (RNeasy Mini Kit, Qiagen). These standards were used to
produce standard curves for absolute quantitation of glycoprotein D and interferon β
mRNA transcripts isolated from the samples. The RNA concentration and purity of the
mRNA standards was determined with a BioPhotometer 6131 spectrophotometer
(Eppendorf, Westbury, NY). The numbers of RNA copies were estimated based on the
molecular weights of the RNA standards and the RNA concentrations. Ten-fold serial
dilutions were prepared, and aliquots of each dilution were stored at -80° C and used only
once.
Standard curves were generated by testing dilutions of the standard RNAs by realtime RT-PCR and the standard curves were generated by the SmartCycler® II software
(Cepheid). The intra-assay and inter-assay coefficients of variation of the reactions were
determined using dilutions of the standard RNAs as previously described (34). To ensure
the standard RNAs and the target RNAs were amplified with similar efficiencies (based
on the calculation: Efficiency = [10-1/slope)] -1) (38), four 10-fold serial dilutions of RNA
extracted from an FHV infected control well and RNA extracted from a Calici infected
interferon β control well were also prepared and tested by real-time RT-PCR.
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Results
FHV-1 glycoprotein D specific siRNAs inhibit glycoprotein D mRNA and
protein expression: To examine if glycoprotein D expression could be knocked down by
RNA interference, three 27-mer and three 21-mer siRNAs were designed to target five
different areas of glycoprotein D mRNA. The siRNAs were transfected into cells prior to
infection with FHV-1. CRFK cells were effectively transfected with Lipofectamie 2000,
with efficiencies of 95% and greater, based on results from a transfection control siRNA
(data not shown).
Quantitative real time RT-PCR was used to determine glycoprotein D mRNA
knockdown 48 hours after infection. mRNA copy numbers for each sample were
estimated from a standard curve generated by dilutions of standard glycoprotein D RNA.
The standard curve spanned five orders of magnitude, and the curve showed linearity
over the entire range used for quantitation of mRNA (Figure 3.1). The results were
reproducible, with an intra-assay coefficient of variation based on copy numbers of 1021% (0.5-1.24% based on Ct values) and an inter-assay coefficient of variation of 3452% based on copy numbers (1.33-3.40% based on Ct values). The theoretical limit of
detection was 20 copies of glycoprotein D mRNA.
Of the siRNAs tested, one of the 27-mers (gD1) and one of the 21-mers (G3) were
shown to be highly effective, with knockdown of glycoprotein D mRNA by 77% by gD1
and 87% by G3, whereas the rest of the siRNAs were shown to have minimal to moderate
effects compared to control samples transfected with negative control siRNAs (Figure 3.2
and data not shown). The least functional siRNAs, producing approximately 30%
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FIGURE 3.1 FHV-1 glycoprotein D standard curve. The curve was generated by
testing five 10-fold serial dilutions of glycoprotein D standard RNA. The efficiency of
the reaction was 100%, compared to the efficiency of 10-fold serial dilutions of
glycoprotein D mRNA of 101% (not shown). Therefore, this standard curve is suitable
for estimation of copy numbers of glycoprotein D mRNA.
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FIGURE 3.2 Knockdown of FHV-1 glycoprotein D mRNA by siRNAs. CRFK cells
were transfected with gD1 siRNA, G3 siRNA, or negative control siRNA 24 hours prior
to infection with FHV-1 (MOI= 0.1). Following 48 hours incubation, total RNA was
extracted from cells and tested by real-time RT-PCR with primers specific for
glycoprotein D or 28S rRNA. The samples were normalized with 28S rRNA and copies
of glycoprotein D were estimated from the glycoprotein D standard curve. The figure
shows the results from a single representative experiment. Three independent
experiments were performed with similar results. Control = averaged results from 21mer and 27-mer negative control siRNA treated FHV-1 infected cells (not statistically
different, P = 0.26 univariate ANOVA), gD1/G3 = FHV- 1 glycoprotein D specific
siRNAs
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knockdown each, were the 27-mer gD2 and the 21-mer G1, which both targeted the same
region of the coding sequence (data not shown). Therefore, gD1 and G3 were chosen for
additional experiments.
gD1 and G3 siRNAs were also tested in cells infected with FHV-1 (MOI=1) 24
hours following transfection and tested for mRNA knockdown 24 hours following
infection. G3 was effective under these reaction conditions, however; the 27mer gD1
was not effective (data not shown).
Glycoprotein D protein synthesis was assessed in glycoprotein D specific siRNA
treated versus negative siRNA treated cells by flow cytometry. For this test, FHV-1
monoclonal antibodies, donated by Dr. Chris Grant (Custom Monoclonals International),
were characterized by Western blot analysis, flow cytometry, virus neutralization, and
hemagglutination inhibition assays. One monoclonal antibody (FHV 7-5) was shown to
react with an antigen that is approximately 50-60 kDa in size (Figure 3.3), found on the
surface of infected cells by flow cytometry, and inhibited hemagglutination of feline cells
(Figure 3.4). These results suggested this monoclonal detects FHV-1 glycoprotein D (22,
23). However, this monoclonal did not neutralize virus infectivity in the absence of
complement as expected, but this is a variable characteristic based on epitope (23).
Therefore, this antibody was used to assess the amount of glycoprotein D present on the
surface of FHV-1 infected cells transfected with negative control siRNA or with
glycoprotein D specific siRNAs. Knockdown of glycoprotein D by gD1 and G3 siRNAs
decreased glycoprotein D protein expression by 27% and 43%, respectively, compared to
the negative siRNA transfected control (Figure 3.5).
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FIGURE 3.3 Detection of FHV-1 glycoprotein D with FHV 7-5 monoclonal
antibody. Proteins from FHV-1 infected cells were treated with SDS sample buffer,
electrophoresed on a 10% polyacrylamide gel and transferred to a nitrocellulose
membrane (Bio- Rad, Hercules, CA). The membrane was blocked overnight in 5% milk
at 4ºC. The membrane was probed with FHV 7-5 monoclonal antibody for 1 hour at
room temperature. The membrane was washed five times with PBS containing 0.05%
Tween 20 and probed with peroxidase labeled goat anti-mouse IgG (KPL, Gaithersburg,
Maryland) for one hour at room temperature. Five additional washes were performed,
and the protein was detected by enhanced chemiluminescence (Amersham Biosciences,
Piscataway, NJ).

108

C

4

8

16

32

64

128

FIGURE 3.4 Inhibition of FHV-1 hemagglutination by FHV 7-5. A
hemagglutination inhibition test was performed with monoclonal FHV 7-5 and treated
FHV-1 infected CRFK cells by using 0.5% (v/v) feline red blood cells as previously
described (23). C represents the control well, which lacked FHV-1, and the numbers
represent the inverse of two-fold serial dilutions of antibody.
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FIGURE 3.5 FHV-1 glycoprotein D specific siRNAs decrease expression of gD
protein on the surface of infected CRFK cells. Cells were transfected with negative
control siRNA, gD1 (a) or G3 (b) 24 hours prior to FHV-1 infection (MOI = 0.1). 48
hours following infection, cells were incubated with FHV 7-5 monoclonal antibody (gD
specific monoclonal) and FITC labeled (ab’)2 rabbit anti-mouse immunoglobulin G.
Color key: white- uninfected CRFK cells, black- gD1/G3 treated FHV-1 infected cells,
gray- negative control siRNA treated FHV-1 infected cells. Fluorescence intensity
increases from left to right, and 104 cells were analyzed/sample. This experiment was
repeated three times with similar results.
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FHV-1 glycoprotein D specific siRNAs inhibit virus replication: To determine if
knockdown of glycoprotein D mRNA affects virus replication, plaque assays were
performed to quantify the amount of infective virus released into cell culture
supernatants. gD1 was shown to inhibit viral replication by 84%, and G3 inhibited viral
replication by 77%, compared to non-transfected and negative control siRNA transfected,
FHV-1 infected cells (Figure 3.6)
Glycoprotein D specific siRNAs inhibit FHV-1 DNA polymerase mRNA: Based
on the results from the replication study, we expected that interference of glycoprotein D
mRNA should also result in an indirect decrease in all viral mRNAs due to replication
inhibition. So, the effect of gD1 and G3 treatment on FHV-1 DNA polymerase mRNA
copy numbers was determined. The RNA extracted from the cells was tested for FHV-1
DNA polymerase mRNA by real-time RT-PCR with primers specific for FHV-1 DNA
polymerase mRNA (see Part 2). Though no significant decline in the DNA polymerase
mRNA was detected from samples treated individually with gD1 or G3, when the
siRNAs were used together (25 nM gD1, 75 nM G3) to transfect cells 24 hours prior to
FHV-1 infection (MOI = 0.1), a decrease in the DNA polymerase mRNA was detected
(Figure 3.7 and data not shown).
Glycoprotein D specific siRNAs inhibit expression of additional cell surface
proteins: Knockdown of additional FHV-1 proteins by glycoprotein D specific siRNAs
was also evaluated. Known glycoproteins on the surface of FHV-1 infected cells in
addition to glycoprotein D include glycoproteins B, C, and G, and the complex formed by
glycoproteins E and I. Polyclonal antibodies of feline origin were used to evaluate the
potential knockdown of additional glycoproteins in flow cytometry experiments. gD1
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FIGURE 3.6 FHV-1 glycoprotein D specific siRNAs inhibit FHV-1 replication in
CRFK cells. Cells were transfected with negative control siRNA, gD1, or G3 24 hours
prior to FHV-1 infection (MOI= 0.1). 48 hours following infection, cell culture
supernatant was collected and tested in duplicate by plaque assay. The experiment was
repeated three times, and the results are shown as averages from the three experiments,
with error bars representing 1 standard deviation from the means. The titers from the
gD1 and G3 treated samples are statistically different from the titers for the negative
siRNA treated and untransfected control samples (Control), with P values of 0.005 and
0.003, respectively (univariate ANOVA).
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FIGURE 3.7 Indirect decrease of FHV-1 DNA polymerase mRNA by glycoprotein
D specific siRNAs. CRFK cells were transfected with FHV-1 glycoprotein D specific
siRNAs (25 nM gD1 siRNA and 75 nM G3 siRNA) or negative control siRNAs (25 nM
27mer control, 75 nM 21mer control) 24 hours prior to infection with FHV-1 (MOI=
0.1). Following 48 hours incubation, total RNA was extracted from cells and tested by
real-time RT-PCR with primers specific for DNA polymerase mRNA (see Part 2) or 28S
rRNA. The samples were normalized with 28S rRNA and copies of DNA polymerase
mRNA were estimated from a DNA polymerase standard curve generated from ten-fold
serial dilutions of DNA polymerase standard RNA (see Part 2).
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and G3, when used independently, did not display much effect on the other
glycoproteins; however, when used in combination (25 nM gD1, 75 nM G3), produced
significant knockdown in surface FHV-1 glycoproteins on infected cells compared to
negative control siRNA transfected, FHV-1 infected cells (Fig. 3.8 and data not shown).
The siRNA effect produced by glycoprotein D specific siRNAs is specific: The
effect of virus replication suppression by knockdown of the glycoprotein D mRNA in this
study had to be distinguished from non-sequence specific destruction of all viral mRNA
transcripts as a result of induction of the type 1 interferon pathway (18). Interferon
induction has been ruled out in previous studies in epithelial cells by interferon β
detection methods (4, 6). A quantitative real-time RT-PCR assay for detection of
interferon β mRNA in feline cells was designed and used to estimate copy numbers based
on a standard curve produced from an RNA standard. The standard curve generated by
dilutions of the interferon β standard RNA spanned six orders of magnitude, and the
curve showed linearity over the entire range used for quantitation of mRNA (Figure 3.9).
The results were reproducible, with 7-43% intra-assay variation based on copy numbers
(0.38-2.88%, based on Ct values) and 16-41% inter-assay variation based on copy
numbers (0.67-2.87% based on Ct values). The theoretical limit of detection was 25
copies of interferon β mRNA. Results from this study showed that the interferon β
detected in siRNA treated cells was negligible compared to the control sample
(calicivirus infected cells) and similar to the background level detected in infected cells,
not transfected with siRNAs (data not shown). Therefore, the suppression of viral
replication was the result of the knockdown of glycoprotein D mRNA and not due to type
1 interferon production.
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FIGURE 3.8 FHV-1 glycoprotein D specific siRNAs decrease FHV-1 proteins on the
surface of infected CRFK cells. CRFK cells were transfected with FHV-1 glycoprotein
D specific siRNAs (25 nM gD1 siRNA and 75 nM G3 siRNA) or negative control
siRNAs (25 nM 27mer control, 75 nM 21mer control) 24 hours prior to infection with
FHV-1 (MOI= 0.1). Following 48 hours incubation, cells were incubated with
fluorescein isothiocyanate-labeled anti-FHV-1 polyclonal antibody (Accurate Chemical
and Scientific Corp., Westbury, NY). Color key: white- uninfected CRFK cells, blackgD1/G3 siRNA treated FHV-1 infected cells, gray- negative control siRNA treated FHV1 infected cells. Fluorescence intensity increases from left to right, and 104 cells were
analyzed/sample.
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FIGURE 3.9 Interferon β standard curve. The curve was generated by testing six 10fold serial dilutions of interferon β standard RNA. The efficiency of the reaction was
100%, compared to the efficiency of 10-fold serial dilutions of interferon β mRNA of
96% (not shown). This standard curve was used for estimation of copy numbers of
interferon β mRNA, with a theoretical detection limit of 25 copies of RNA.
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Discussion
RNAi has been manipulated in previous experiments for the determination of
viral gene function (19, 26, 27), and we have shown that RNAi can be effectively used in
CRFK cells to knockdown FHV-1 glycoprotein D mRNA when transfected prior to
infection, thereby allowing determination of the function of this gene. Knockdown of
FHV-1 glycoprotein D mRNA resulted in a decrease in the amount of glycoprotein D and
other FHV-1 glycoproteins detected on the surface of infected cells, as well as indirect
decrease of FHV-1 DNA polymerase mRNA, independent of the production of type 1
interferon. FHV-1 glycoprotein D, like its counterpart in herpes simplex virus type 1, is
essential for producing infectious virions in vitro.
Based on these results, we speculate that FHV-1 glycoprotein D is involved with
viral attachment and/or penetration. Knockdown of this protein on the viral envelope
appears to impair entry of the virus into cells, resulting in a reduction in the amount of
infectious virus compared to control samples, but not necessarily the amount of other
viral mRNAs and proteins, except when knockdown is enhanced by using a combination
of two highly functional siRNAs.
Both 21-mer and 27-mer synthetic siRNAs were used in this study. The 27-mers
have been shown to be more potent inducers of RNAi compared to 21-mers and
potentially functional at sites refractive to RNAi by 21-mer siRNAs (17). Interestingly,
Ambion designed a siRNA that targeted a site also determined suitable by the IDT design
tool. However, this particular site was refractory to RNAi by both types of siRNAs. The
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Mfold program (25, 39) was used to predict the glycoprotein D mRNA structure, and we
discovered that despite the amenable sequence, the target site is likely self-annealed in a
helix in its energetically most favorable structure (data not shown), which has been
previously shown to inhibit RNAi (35).
Also of interest, the 27-mer siRNA (gD1) was not functional in knockdown of
glycoprotein D mRNA 24 hours after infection of cells with a multiplicity of infection of
1, but the 21-mer (G3) was functional. We attribute this to the fact that unlike the 21mer, the 27-mer has to be processed by Dicer. RNA silencing is generally maximal at
approximately 24 hours post-transfection (14). However, in an RNAi study in rotavirus,
the highest suppression was found to occur with infection of cells with rotavirus 72 hours
after transfection with siRNAs, suggesting some of the elements of RNAi could be
induced or activated by the presence of siRNAs, increasing their effective concentration
inside the cell (2).
We also discovered the 27-mer siRNAs were toxic to cells in a concentration
dependent manner, likely resulting from off-target effects with increased concentrations
of siRNA leading to a stress response within the cell (31). Therefore, the 27-mer siRNA
(gD1) was determined to be less toxic and functional at a concentration lower than what
was used for the 21-mer siRNA (G3).
Off-target effects may include stimulation and suppression of expression of genes
unrelated to the intended target (31, 33). These effects appear to be sequence-related;
siRNAs may cross-react with mRNAs of limited sequence homogeneity (13). Therefore,
observing the same phenotype with multiple individual siRNAs targeting the same gene
increases the confidence that the knockdown of the intended gene can be attributed to the
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observed phenotype (14, 15). We were able to show the same effects with two different
siRNAs targeting two different areas of the glycoprotein D mRNA, strengthening our
findings.
FHV-1 glycoprotein D appears to function similarly to its counterpart in herpes
simplex virus type 1 and is a suitable target for suppressing FHV-1 viral infection in
cells. It is therefore a potential target for anti-viral therapy; although, as a structural
protein, it is not transcribed until “late” in infection, and may not be as good a target as a
gene transcribed early in the infection process (16, 28), such as the FHV-1 DNA
polymerase gene (see Part 2). However, use of siRNAs targeting this gene could be
successfully used in combination with siRNAs targeting the DNA polymerase gene, also
reducing the potential for development of escape mutants (37), and likely will be more
effective than targeting a single gene (30).
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Part 4 General Summary
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Feline herpesvirus 1 (FHV-1) glycoprotein D is an important contributor to the
immune response to FHV-1 infection, and neutralizing antibodies against this protein are
produced in cats during infection (9, 10). The glycoprotein D homolog in the related
alphaherpesvirus, herpes simplex virus type 1, contributes to host cell attachment and is
necessary for entry of the virus into cells (7, 8, 11). It was hypothesized that glycoprotein
D has a similar role in FHV-1 infection and that this gene and the FHV-1 DNA
polymerase gene would be appropriate targets to alter viral replication, by inhibiting
entry of the virus into the cells (glycoprotein D) or by directly inhibiting replication of
the viral genome (DNA polymerase). RNA interference was used to knockdown the
expression of FHV-1 glycoprotein D and DNA polymerase genes in CRFK cells. In both
experiments, knockdown of the intended target did result in suppression of virus
replication in vitro.
Knockdown of glycoprotein D mRNA in this study significantly decreased the
amount of infectious virus released into the cell culture supernatant. Knockdown of the
mRNA with two highly functional siRNAs (70% knockdown or greater) transfected
separately was not sufficient enough to knockdown other viral mRNAs, such as the DNA
polymerase mRNA, or the expression of other viral glycoproteins. This phenomenon was
also seen in a previous study with RNAi of the rotavirus attachment protein, VP4 (3).
However, when silencing of the glycoprotein D mRNA was enhanced by using the two
siRNAs combined, significantly detectable knockdown of DNA polymerase mRNA and
FHV-1 proteins on the surface of infected cells was achieved, with an obvious decrease
in the amount of cytopathic effect (CPE) produced in cell culture.
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RNAi does not prevent the initial entry of virions into the cells, and by targeting
the glycoprotein D gene (a structural protein, transcribed late in infection), the first round
of viral replication is unaffected. Knockdown of glycoprotein D expression reduces the
amount of the protein incorporated into the viral envelope, altering the infectivity of the
virions and presumably inhibiting some but not all from infecting cells. Therefore, when
knockdown is enhanced, seemingly more virions are inhibited from infecting cells,
resulting in a detectable decrease in the amount of viral mRNAs in addition to the
glycoprotein D mRNA detected inside the cells and enough decrease in the number of
replicating virions to have a significant suppressive effect on the expression of additional
viral glycoproteins. Unfortunately, the amount of viral DNA in the cell culture
supernatants was not determined in this study, nor was the amount of infectious virus
associated with the infected cells, to corroborate this idea. Based on the findings in this
study, though, glycoprotein D is a potential target for RNAi anti-viral therapy.
However, targeting a gene transcribed earlier in viral infection likely will have a
more significant affect on virus replication (4). This was shown to be the case in this
study. Targeting the DNA polymerase gene of FHV-1, an early gene, resulted in
significant reduction in cytopathic effect produced in cells treated individually with two
different siRNAs (DNA1 and DNA3). Compared to the controls (FHV infected/ nontransfected and FHV infected/ negative control siRNA transfected cells), which contained
3-4+ CPE, cells treated with DNA1 had 1-2+ CPE and cells treated with DNA3 had 2-3+
CPE. By targeting the DNA polymerase gene, there is a direct reduction of viral
replication, potentially starting with the first round of replication. Therefore, though
knockdown of the amount of DNA polymerase mRNA by DNA3 was significantly less
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than what was achieved for glycoprotein D mRNA by the glycoprotein D specific
siRNAs, there was better indirect knockdown of other viral mRNA (glycoprotein D) and
viral proteins on the surface of infected cells with this individual DNA polymerase
specific siRNA.
For anti-viral therapy, targeting multiple viral genes is likely the best method to
prevent production of escape mutants (17), and has been shown to be more effective in
vivo in a herpesvirus study than targeting a single gene (12). Thus, use of siRNAs
targeting both the glycoprotein D and DNA polymerase genes is probably the best
strategy for the most efficient suppression of FHV-1 replication, though this experiment
was not performed in this study.
In addition to choosing the best genes to target, efficient transfection of siRNAs
into cells is important for successful RNAi experiments. Efficient transfection was
achieved in this study with Lipofectamine 2000; however, a suboptimal concentration of
transfection reagent had to be used to reduce cellular toxicity. The reagent was toxic to
cells in a concentration dependent manner (data not shown). Not all toxicity could be
eliminated and cells showed mild granularity, with more dead cells in transfected samples
compared to non-transfected controls.
Also, transfection was unsuccessful in cells pre-plated in medium containing
antibiotics 24 hours prior to transfection (data not shown); so, reverse transfections were
used in this study, with cells added to transfection mixtures. It was not determined if it
was the antibiotics in the cell culture medium, or the plated cells, or a combination of
both that prevented transfection of the plated cells. The antibiotics in the medium during
the transfection process did not kill the cells, and addition of antibiotics to the medium
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four hours after transfection had no negative effects on the transfection efficiency.
However, transfection was shown to be complete after four hours incubation, so
antibiotics added at that point would not have affected transfection efficiency anyway.
An additional observation concerning this transfection reagent was that
concentrations of siRNA below 50 nM resulted in transfection efficiencies below 95%
(data not shown). So, determining the optimal concentration of siRNAs to obtain the
highest knockdown with the least amount of cellular toxicity was not possible in the cell
culture system used in this study with this transfection reagent. Therefore, a different
type of transfection reagent would likely be indicated for future studies.
Design of siRNAs may be more important for effective targeting than the method
of delivery of siRNAs into cells (5). Chemically produced 21-mer and 27-mer siRNAs
were used in this study. 27-mers were used because they had been shown to be more
effective than 21-mers (6). One of six 27-mers (3 glycoprotein D specific and 3 DNA
polymerase specific) tested in this study was found to be highly functional (70% or
greater knockdown of intended target). Two of the 27-mers targeted the same regions as
two of the 21-mers. One of these 27-mers targeted the same sequence as one of the
functional DNA polymerase specific 21-mer siRNAs, DNA3. When initially tested, the
27-mer designed to target this area produced 60% knockdown of DNA polymerase
mRNA, less than the amount required to be considered highly functional, so it was not
tested further (data not shown). So, for this particular target area, the 21-mer seemed to
function better, but optimal concentrations of the 27-mer were not determined and the
increased potency of 27-mers is really only obvious at subnanomolar concentrations (6),
which were not used in this study.
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The sequence of each individual siRNA is obviously important to its function
because it facilitates the association with RISC and subsequent degradation of target
mRNA (5). The most important criterion in siRNA design appears to be asymmetry in
the stability of the duplex ends. The 5’ end of the antisense strand should be less
thermodynamically stable than the 3’ end (1, 13) This facilitates the use of the antisense
strand as the guide strand by RISC (5, 14). Of the DNA polymerase specific siRNAs
tested, the two most effective siRNAs contained 5’ ends that were less
thermodynamically stable than the 3’ends, and the least functional siRNA (DNA2) had a
more stable 5’ end.
Also, in this study, as has been shown previously (16), the secondary structure of
the target mRNA appeared to be an important determinant of whether some siRNAs
would work well. The other region targeted by both a 21-mer and 27-mer siRNA was
within the glycoprotein D mRNA. Neither siRNA was functional for this target region,
which is predicted to be self-annealed in its energetically most favorable state and likely
not accessible to the RNAi machinery. The least functional DNA polymerase specific
siRNA tested (DNA2) was also predicted to be completely self-annealed. Whereas, the
two most functional DNA polymerase specific siRNAs contained several bases that were
in loop structures, including the 3’ end of the coding sequence targeted by DNA1, the
most effective DNA polymerase specific siRNA in the study.
Despite the complications in designing functional siRNAs, RNAi has been shown
to be effective in the prevention/ treatment of infections by several different viruses (4).
This study examined prevention of FHV-1 infection in vitro and because transfection of
cells with siRNAs after infection was not performed, treatment of FHV-1 by RNAi was
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not addressed. FHV-1 replicates rapidly in cell culture. Infectious intracellular virus can
be detected six hours post infection, and cell-to-cell spread of virus can be detected six to
seven hours post infection. Extracellular spread of the virus occurs at nine to ten hours
post infection, concurrent with detection of infectious extracellular virus (15). Therefore,
it is probable that RNAi, by itself, may not be very effective to treat an established
infection, but a combination of RNAi and nucleoside analogs might encounter a
synergistic effect (4) for treatment of chronic FHV-1 ocular infections in cats. RNAi
might be more useful for prevention of FHV-1 infections in situations associated with
increased risk for respiratory disease, such as in breeding colonies and rescue catteries
(2). Or, RNAi could potentially be used to prevent the recrudescence of latent infections
in chronically infected cats. Regardless, with the current lack of effective treatments for
this disease in chronically infected cats, RNAi has merit as a potential FHV-1 anti-viral
therapy.
This study lays the groundwork for potential in vivo investigations in cats. Such
studies may provide unique insights into the prevention/treatment of herpesvirus
infections by RNAi.
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